1 00:00:05,640 --> 00:00:09,440 >>GOOD AFTERNOON AND THANK YOU 2 00:00:09,440 --> 00:00:14,160 FOR JOINING OUR WEBINAR. 3 00:00:14,160 --> 00:00:16,080 I'M ANITA McRAE-WILLIAMS PLEASED 4 00:00:16,080 --> 00:00:18,160 TO SERVE AS YOUR MODERATOR. 5 00:00:18,160 --> 00:00:22,600 I OVERSEE OUTREACH COMMUNICATION 6 00:00:22,600 --> 00:00:31,600 FOR THE EXTRA -- EXTERNAL 7 00:00:31,600 --> 00:00:33,280 COMMUNITY FOR THE NCCIH AND THIS 8 00:00:33,280 --> 00:00:34,360 IS TO PROVIDE YOU WITH AN 9 00:00:34,360 --> 00:00:37,640 OPPORTUNITY TO HEAR MORE ABOUT 10 00:00:37,640 --> 00:00:40,600 THE NOTICE FOR FUNDING 11 00:00:40,600 --> 00:00:45,520 OPPORTUNITY TITLE, HEAL 12 00:00:45,520 --> 00:00:49,320 INITIATIVE TOWARD DEVELOPING 13 00:00:49,320 --> 00:00:53,480 QUANTITATIVE IMAGING THE OTHER 14 00:00:53,480 --> 00:00:55,520 RELEVANT BIOMARKERS FOR OFFICIAL 15 00:00:55,520 --> 00:00:57,480 TISSUES FOR CLINICAL PAIN 16 00:00:57,480 --> 00:00:59,000 MANAGEMENT INFORMATION WEBINAR 17 00:00:59,000 --> 00:01:01,560 AND THIS IS A RFA-AT-24-003 18 00:01:01,560 --> 00:01:02,720 WEBINAR AND YOU'LL HAVE AN 19 00:01:02,720 --> 00:01:04,640 OPPORTUNITY TO HAVE YOUR 20 00:01:04,640 --> 00:01:06,560 QUESTIONS ANSWERED DURING THE 21 00:01:06,560 --> 00:01:07,200 LATTER PORTION FF THE TECHNICAL 22 00:01:07,200 --> 00:01:10,360 ASSISTANCE WEBINAR IS ONE HOUR 23 00:01:10,360 --> 00:01:12,000 IN LENGTH AND DURING THE FIRST 24 00:01:12,000 --> 00:01:14,760 HALF OF THE WEBINAR YOU'LL HEAR 25 00:01:14,760 --> 00:01:17,000 PRESENTATIONS FROM NCCIH'S 26 00:01:17,000 --> 00:01:18,240 DIRECTOR AND NCCIH PROGRAM AND 27 00:01:18,240 --> 00:01:20,840 REVIEW STAFF. 28 00:01:20,840 --> 00:01:22,800 THE LATTER HALF OF THE WEBINAR 29 00:01:22,800 --> 00:01:27,480 IS ENTIRELY DEVOTED TO ANSWERING 30 00:01:27,480 --> 00:01:29,400 QUESTIONS IN THE VIEWING 31 00:01:29,400 --> 00:01:32,360 AUDIENCE AND YOUR QUESTIONS CAN 32 00:01:32,360 --> 00:01:34,120 BE SUBMITTED USING THE VIDEOCAST 33 00:01:34,120 --> 00:01:36,640 FEEDBACK FORM. 34 00:01:36,640 --> 00:01:41,760 AND THAT IS BELOW YOUR SCREEN IT 35 00:01:41,760 --> 00:01:43,880 IS A LIGHT GRAY ICON FOR THE 36 00:01:43,880 --> 00:01:44,240 FEEDBACK FORM. 37 00:01:44,240 --> 00:01:45,800 WE LOOK FORWARD TO RECEIVING 38 00:01:45,800 --> 00:01:46,600 YOUR QUESTIONS. 39 00:01:46,600 --> 00:01:49,480 AGAIN, YOU CAN SUBMIT THEM AT 40 00:01:49,480 --> 00:01:49,840 ANY TIME. 41 00:01:49,840 --> 00:01:52,400 PLEASE NOTE ATTENDANCE AT THE 42 00:01:52,400 --> 00:01:54,360 TECHNICAL ASSISTANCE WEBINAR IS 43 00:01:54,360 --> 00:01:56,520 OPTIONAL AND NOT A REQUIREMENT 44 00:01:56,520 --> 00:01:57,680 FOR APPLICATION SUBMISSION. 45 00:01:57,680 --> 00:02:00,200 THIS WEBINAR IS BEING VIDEOCAST 46 00:02:00,200 --> 00:02:02,840 AND WILL BE ARCHIVED FOR LATER 47 00:02:02,840 --> 00:02:08,520 VIEWING AND WILL BE AVAILABLE 48 00:02:08,520 --> 00:02:11,080 FOR REBROADCAST TOMORROW ON THE 49 00:02:11,080 --> 00:02:14,600 NIH EVENTS PAGE UNDER PAST 50 00:02:14,600 --> 00:02:15,040 EVENTS. 51 00:02:15,040 --> 00:02:16,520 NOW, IT IS MY PLEASURE TO 52 00:02:16,520 --> 00:02:19,400 INTRODUCE OUR SPEAKERS FOR 53 00:02:19,400 --> 00:02:19,880 TODAY'S WEBINAR. 54 00:02:19,880 --> 00:02:22,320 OUR VERY FIRST SPEAKER IS IS 55 00:02:22,320 --> 00:02:32,880 DR. HELENE LANGEVIN THE DIRECTOR 56 00:02:35,160 --> 00:02:36,560 FOR NCCIH. 57 00:02:36,560 --> 00:02:39,640 SHE BECAME THE DIRECTOR OF NCCIH 58 00:02:39,640 --> 00:02:41,560 IN 2018. 59 00:02:41,560 --> 00:02:42,960 FOLLOWING HER TENURE OF THE 60 00:02:42,960 --> 00:02:46,760 CENTER FOR INTEGRATIVE MEDICINE 61 00:02:46,760 --> 00:02:50,080 IN BOSTON JOINTLY BASED AT 62 00:02:50,080 --> 00:02:54,160 BRIGHAM AND WOMEN'S HOSPITAL AND 63 00:02:54,160 --> 00:02:56,760 HARVARD MEDICAL SCHOOL. 64 00:02:56,760 --> 00:02:58,800 AS NCCIH DIRECTOR SHE OVERSEES 65 00:02:58,800 --> 00:03:00,200 THE FEDERAL GOVERNMENT'S LEAD 66 00:03:00,200 --> 00:03:02,640 AGENCY FOR RESEARCH ON THE 67 00:03:02,640 --> 00:03:04,520 FUNDAMENTAL SCIENCE, USEFULNESS 68 00:03:04,520 --> 00:03:06,160 AND SAFETY OF COMPLIMENTARY AND 69 00:03:06,160 --> 00:03:07,480 INTEGRATIVE HEALTH APPROACHES 70 00:03:07,480 --> 00:03:09,480 AND THEIR WELLNESS IN IMPROVING 71 00:03:09,480 --> 00:03:11,520 HEALTH AND HEALTH CARE. 72 00:03:11,520 --> 00:03:13,640 WITH THE ANNUAL BUDGET OF 73 00:03:13,640 --> 00:03:16,840 APPROXIMATELY $170 MILLION, 74 00:03:16,840 --> 00:03:20,280 NCCIH FUNDS AND CONDUCTS 75 00:03:20,280 --> 00:03:21,960 RESEARCH TO HELP ANSWER 76 00:03:21,960 --> 00:03:23,480 IMPORTANT SCIENTIFIC AND PUBLIC 77 00:03:23,480 --> 00:03:26,160 HEALTH QUESTIONS WITHIN THE 78 00:03:26,160 --> 00:03:29,840 CONTEXT OF WHOLE PERSON HEALTH. 79 00:03:29,840 --> 00:03:33,440 FOLLOWING, DR. LANGEVIN THE NEXT 80 00:03:33,440 --> 00:03:36,040 SPEAKER IS IS DR. ALEX TUTTLE IN 81 00:03:36,040 --> 00:03:39,600 THE BASIC AND MECHANISTIC 82 00:03:39,600 --> 00:03:42,160 RESEARCH BRANCH AT THE CENTER 83 00:03:42,160 --> 00:03:45,360 FOR NCCIH WHERE HE OVERSEES THE 84 00:03:45,360 --> 00:03:51,000 MANUAL THERAPY AND MANIPULATION 85 00:03:51,000 --> 00:03:52,920 PORTFOLIOS AND THE PAIN AND 86 00:03:52,920 --> 00:03:55,080 CLINICAL AND TRANSLATIONAL 87 00:03:55,080 --> 00:03:55,880 RESEARCH PORTFOLIO. 88 00:03:55,880 --> 00:03:59,280 HE HEADS SEVERAL NCCIH WIDE 89 00:03:59,280 --> 00:04:01,480 INITIATIVES INCLUDING HELPING TO 90 00:04:01,480 --> 00:04:05,720 END ADDICTION LONG TERM THE HEAL 91 00:04:05,720 --> 00:04:07,640 INITIATIVE, MYOFASCIAL PAIN 92 00:04:07,640 --> 00:04:09,480 BIOMARKERS PROGRAM IN THE JOINT 93 00:04:09,480 --> 00:04:10,680 NCCIH NATIONAL INSTITUTE OF 94 00:04:10,680 --> 00:04:15,480 NEUROLOGICAL DISORDERS AND 95 00:04:15,480 --> 00:04:20,280 STROKE AND RESEARCH MANIPULATION 96 00:04:20,280 --> 00:04:20,520 PROGRAM. 97 00:04:20,520 --> 00:04:23,240 LAST SPEAKER IS DR. SHIYONG 98 00:04:23,240 --> 00:04:25,840 HUANG IN THE NCCIH'S OFFICE OF 99 00:04:25,840 --> 00:04:27,760 SCIENTIFIC REVIEW AND THE REVIEW 100 00:04:27,760 --> 00:04:31,520 OFFICER ASSIGNED TO THIS 101 00:04:31,520 --> 00:04:31,800 OPPORTUNITY. 102 00:04:31,800 --> 00:04:36,680 IN THIS CAPACITY, HE ORGANIZED 103 00:04:36,680 --> 00:04:38,000 SPECIAL EMPHASIS PANELS IN 104 00:04:38,000 --> 00:04:40,520 RESPONSE TO FUNDING 105 00:04:40,520 --> 00:04:42,040 OPPORTUNITIES LED BY NCCIH. 106 00:04:42,040 --> 00:04:44,480 SO WITH THAT, I WILL TURN IT 107 00:04:44,480 --> 00:04:50,160 OVER TO OUR FIRST SPEAKER, 108 00:04:50,160 --> 00:04:52,240 DR. HELENE LANGEVIN. 109 00:04:52,240 --> 00:04:54,240 >>THANK YOU, VERY MUCH, ANITA 110 00:04:54,240 --> 00:04:55,720 FOR STARTING US OFF. 111 00:04:55,720 --> 00:04:57,520 I'M GOING START SHARING A COUPLE 112 00:04:57,520 --> 00:04:59,240 OF SLIDES. 113 00:04:59,240 --> 00:05:03,320 GIVE YOU SOME BACKGROUND AS TO 114 00:05:03,320 --> 00:05:06,160 HOW AND WHY THIS INITIATIVE CAME 115 00:05:06,160 --> 00:05:10,760 ABOUT AND WHY WE WANT TO PROVIDE 116 00:05:10,760 --> 00:05:12,640 THIS OPPORTUNITY FOR REISSUING 117 00:05:12,640 --> 00:05:15,840 THE INITIATIVE AND INVITING MORE 118 00:05:15,840 --> 00:05:18,280 PEOPLE TO SUBMIT GRANT 119 00:05:18,280 --> 00:05:20,360 APPLICATIONS. 120 00:05:20,360 --> 00:05:23,720 SO THIS WHOLE PROJECT CAME ABOUT 121 00:05:23,720 --> 00:05:26,120 FROM THE VERY VEXING PROBLEM IN 122 00:05:26,120 --> 00:05:33,520 THAT A LARGE PROPORTION OF THE 123 00:05:33,520 --> 00:05:39,280 CHRONIC MUSCULOSKELETAL PAIN 124 00:05:39,280 --> 00:05:41,200 PEOPLE EXPERIENCE WHETHER PAIN 125 00:05:41,200 --> 00:05:43,280 IN THE NECK, LOWER BACK IT'S 126 00:05:43,280 --> 00:05:45,520 REMARKABLE WE DON'T KNOW AND WE 127 00:05:45,520 --> 00:05:46,440 WANT TO ADDRESS THAT. 128 00:05:46,440 --> 00:05:48,560 THIS IS A SCENARIO I'M SURE MANY 129 00:05:48,560 --> 00:05:50,000 OF YOU WILL RECOGNIZE. 130 00:05:50,000 --> 00:05:52,040 IT HAPPENS QUITE A LOT. 131 00:05:52,040 --> 00:05:54,160 SOMEBODY WHO SPENDS A GOOD PART 132 00:05:54,160 --> 00:06:04,120 OF THE WEEK IN EITHER SAEDENTAR 133 00:06:04,120 --> 00:06:07,560 POSITION AND UNDER GOES A BURST 134 00:06:07,560 --> 00:06:09,120 OF ACTIVITY ON THE WEEKEND AND 135 00:06:09,120 --> 00:06:10,760 SUFFERS THE CONSEQUENCES 136 00:06:10,760 --> 00:06:11,960 AFTERWARDS IN THE FORM OF 137 00:06:11,960 --> 00:06:15,040 PAINFUL AND KNOTS AND AREAS 138 00:06:15,040 --> 00:06:16,200 WHERE THE TISSUES FEEL LIKE 139 00:06:16,200 --> 00:06:20,120 THEY'RE TENDER AND SORT OF HARD 140 00:06:20,120 --> 00:06:23,600 TO TOUCH AND WHAT CAUSES THIS IS 141 00:06:23,600 --> 00:06:25,080 QUITE AMAZING THAT WE DO NOT 142 00:06:25,080 --> 00:06:27,080 UNDERSTAND THE PATHOPHYSIOLOGY 143 00:06:27,080 --> 00:06:29,480 OF THESE PROBLEMS. 144 00:06:29,480 --> 00:06:31,720 AND PEOPLE WHO DO VARIOUS FORMS 145 00:06:31,720 --> 00:06:33,560 OF MANUAL THERAPY, FOR EXAMPLE, 146 00:06:33,560 --> 00:06:36,240 PHYSICAL THERAPY AND MASSAGE, 147 00:06:36,240 --> 00:06:37,560 VARIOUS FORMS OF MANUAL 148 00:06:37,560 --> 00:06:39,480 THERAPIES FEEL A PRACTITIONER 149 00:06:39,480 --> 00:06:42,160 AND WHEN YOU PUT YOUR HANDS ON 150 00:06:42,160 --> 00:06:43,640 AN AREA OF SOMEBODY, THE AREA 151 00:06:43,640 --> 00:06:46,200 WHERE IT HURTS, YOU FEEL THE 152 00:06:46,200 --> 00:06:48,480 TISSUES DO NOT FEEL NORMAL TO 153 00:06:48,480 --> 00:06:49,320 THE TOUCH. 154 00:06:49,320 --> 00:06:54,560 THERE'S A SENSATION OF INCREASED 155 00:06:54,560 --> 00:06:56,400 RESISTANCE TO PALPATION, 156 00:06:56,400 --> 00:06:58,120 SOMETIMES A SENSATION THE 157 00:06:58,120 --> 00:07:00,040 TISSUES ARE NOT MOVING OR 158 00:07:00,040 --> 00:07:02,120 GLIDING PROPERLY BUT WE DO HAVE 159 00:07:02,120 --> 00:07:04,120 GOOD WAYS TO MEASURE THIS YET AT 160 00:07:04,120 --> 00:07:05,880 THE MOMENT AND WE DON'T REALLY 161 00:07:05,880 --> 00:07:09,520 THE AND FOR THAT REASON THIS IS 162 00:07:09,520 --> 00:07:13,840 REALLY BEEN A FACTOR THAT HAS 163 00:07:13,840 --> 00:07:18,160 CAUSED THE RESEARCH ON 164 00:07:18,160 --> 00:07:19,400 MYOFASCIAL PAIN AND 165 00:07:19,400 --> 00:07:20,600 UNDERSTANDING THE COMPONENTS OF 166 00:07:20,600 --> 00:07:22,080 THE MUSCLES AND CONNECTIVE 167 00:07:22,080 --> 00:07:23,160 TISSUES THAT SURROUND THE 168 00:07:23,160 --> 00:07:24,200 MUSCLES. 169 00:07:24,200 --> 00:07:26,040 WE DON'T REALLY KNOW THE 170 00:07:26,040 --> 00:07:27,520 CONTRIBUTION OF THESE TISSUES TO 171 00:07:27,520 --> 00:07:31,480 THE PATHOPHYSIOLOGY OF 172 00:07:31,480 --> 00:07:33,280 MUSCULOSKELETAL PAIN. 173 00:07:33,280 --> 00:07:36,520 SO WE HAD A WONDERFUL WORKSHOP A 174 00:07:36,520 --> 00:07:41,600 COUPLE YEARS AGO ON THIS AND 175 00:07:41,600 --> 00:07:42,520 SOME OF THESE PROBLEMS THAT 176 00:07:42,520 --> 00:07:44,080 MIGHT -- AND THESE ARE STILL AT 177 00:07:44,080 --> 00:07:46,160 THE LEVEL OF HYPOTHESES THAT 178 00:07:46,160 --> 00:07:49,320 MIGHT EXPLAIN BOTH THE PAIN AS 179 00:07:49,320 --> 00:07:51,800 WELL AS THE TENDERNESS TO 180 00:07:51,800 --> 00:07:57,320 PALPATION AND THE PALPATORY 181 00:07:57,320 --> 00:07:59,800 FINDINGS PRACTITIONERS CAN 182 00:07:59,800 --> 00:08:02,560 OBSERVE AND SOME HYPOTHESES ARE 183 00:08:02,560 --> 00:08:05,840 RELATED TO THE MUSCLE. 184 00:08:05,840 --> 00:08:09,320 FOCAL AREAS WHERE THE MUSCLE 185 00:08:09,320 --> 00:08:11,520 FIBERS ARE CHRONICALLY 186 00:08:11,520 --> 00:08:12,720 CONTRACTED FORMING THE TOUGH 187 00:08:12,720 --> 00:08:15,520 BANDS AND THE OTHER POSSIBILITY 188 00:08:15,520 --> 00:08:17,840 IS ABNORMALITIES IN THE REFLEXES 189 00:08:17,840 --> 00:08:21,520 THAT CAUSES CONTRACTIONS AND IN 190 00:08:21,520 --> 00:08:25,520 THE SHORTENINGS INCLUDING 191 00:08:25,520 --> 00:08:27,080 POSSIBLE INFLAMMATION OR 192 00:08:27,080 --> 00:08:30,440 REDUCTION IN PH, FOR EXAMPLE, 193 00:08:30,440 --> 00:08:32,360 PERHAPS DUE TO CHRONIC LACTIC 194 00:08:32,360 --> 00:08:33,840 ACID IN THE AREAS OF COULD BE 195 00:08:33,840 --> 00:08:36,120 TRACTION. 196 00:08:36,120 --> 00:08:37,160 -- CONTRACTION. 197 00:08:37,160 --> 00:08:38,560 ANOTHER POSSIBILITY IS THAT 198 00:08:38,560 --> 00:08:41,520 THERE'S A PROBLEM NOT IN THE 199 00:08:41,520 --> 00:08:43,600 MUSCLE ITSELF BUT IN THE FASCIA 200 00:08:43,600 --> 00:08:45,040 EITHER OVERLYING THE MUSCLE AND 201 00:08:45,040 --> 00:08:47,320 IN BETWEEN THE SKIN AND THE 202 00:08:47,320 --> 00:08:48,920 MUSCLE FOR EXAMPLE IN THE SUB 203 00:08:48,920 --> 00:08:50,360 CUTANEOUS TISSUE. 204 00:08:50,360 --> 00:08:55,480 THERE COULD BE INCREASED 205 00:08:55,480 --> 00:08:58,080 STIFFNESS OR DENSIFICATION IN 206 00:08:58,080 --> 00:09:02,880 TERMS OF HYALURONIC ACID 207 00:09:02,880 --> 00:09:05,640 ACCUMULATION OR CLUMPING OR 208 00:09:05,640 --> 00:09:07,640 PROBLEMS WITH WATER DISTRIBUTION 209 00:09:07,640 --> 00:09:09,400 IN THE TISSUE CAUSING STIFFNESS 210 00:09:09,400 --> 00:09:11,440 AND REDUCTION IN THE MOBILITY 211 00:09:11,440 --> 00:09:12,720 AND IMPORTANTLY ENOUGH THERE 212 00:09:12,720 --> 00:09:15,320 COULD BE A COMBINATION OF THESE 213 00:09:15,320 --> 00:09:17,000 PROBLEMS AND MAY BE THEY'RE 214 00:09:17,000 --> 00:09:19,480 COMPONENTS OF MUSCLE AND FASCIA 215 00:09:19,480 --> 00:09:22,160 THAT CONTRIBUTE THAT MAY BE 216 00:09:22,160 --> 00:09:23,560 MUTUALLY REINFORCING. 217 00:09:23,560 --> 00:09:34,120 AS MENTIONED WE HAD A WORKSHOP 218 00:09:39,520 --> 00:09:42,160 IN DECEMBER 2020 WE IDENTIFIED 219 00:09:42,160 --> 00:09:45,120 MANY AREAS THAT WERE GAPS IN 220 00:09:45,120 --> 00:09:46,520 RESEARCH. 221 00:09:46,520 --> 00:09:47,440 AS A RESULT, WE ISSUED 222 00:09:47,440 --> 00:09:50,960 PREVIOUSLY A REQUEST FOR 223 00:09:50,960 --> 00:09:53,360 APPLICATION IB 2022 AND THIS WAS 224 00:09:53,360 --> 00:09:58,160 PART OF THE HEAL INITIATIVE OR 225 00:09:58,160 --> 00:10:00,000 WHICH STANDS FOR HELPING END 226 00:10:00,000 --> 00:10:00,760 ADDICTION LONG TERM. 227 00:10:00,760 --> 00:10:04,440 THIS IS A VERY LARGE TRANS-NIH 228 00:10:04,440 --> 00:10:07,840 PROGRAM BASED ON -- AIMED AT 229 00:10:07,840 --> 00:10:09,520 ADDRESSING THE OPIOID CRISIS. 230 00:10:09,520 --> 00:10:11,640 AND OPIOID ADDICTION AND IN 231 00:10:11,640 --> 00:10:13,360 TERMS OF INFORMATION AND BETTER 232 00:10:13,360 --> 00:10:14,600 TREATING PAIN. 233 00:10:14,600 --> 00:10:17,800 THE HEAL INITIATIVE FUNDED 234 00:10:17,800 --> 00:10:18,480 SEVERAL APPLICATIONS IN RESPONSE 235 00:10:18,480 --> 00:10:20,880 TO AND HAD A GOOD RESPONSE TO 236 00:10:20,880 --> 00:10:22,120 THE FIRST REQUEST FOR 237 00:10:22,120 --> 00:10:25,200 APPLICATION AND WE ENDED UP 238 00:10:25,200 --> 00:10:26,240 FUNDING AN APPLICATION AND 239 00:10:26,240 --> 00:10:30,040 GIVING YOU A SNAPSHOT OF THE 240 00:10:30,040 --> 00:10:31,360 KINDS OF TECHNOLOGIES AND THE 241 00:10:31,360 --> 00:10:35,360 PURPOSE OF THE WORKSHOP WAS TO 242 00:10:35,360 --> 00:10:38,160 DEVELOP TOOLS TO INTERROGATE AND 243 00:10:38,160 --> 00:10:42,160 DEVELOP QUANTITATIVE OBJECTIVE 244 00:10:42,160 --> 00:10:45,040 MARKERS OF MYOFASCIAL TISSUES IN 245 00:10:45,040 --> 00:10:48,160 RELATIONSHIP TO MYOFASCIAL PAIN 246 00:10:48,160 --> 00:10:53,080 AND TO FIRST PHASE IS THE 247 00:10:53,080 --> 00:10:53,960 DEVELOPMENT AND ALEX WILL TELL 248 00:10:53,960 --> 00:10:56,480 US MORE ABOUT THAT AS TO WHAT 249 00:10:56,480 --> 00:10:57,520 THE DIFFERENT PHASES ARE. 250 00:10:57,520 --> 00:10:59,760 THE FIRST IS TO DEVELOP THE 251 00:10:59,760 --> 00:11:02,120 TOOLS AND THE SECOND PHASE IS TO 252 00:11:02,120 --> 00:11:04,600 TEST THEM IN RESPONSE TO AN 253 00:11:04,600 --> 00:11:07,480 INTERVENTION THAT CAN BE USED 254 00:11:07,480 --> 00:11:08,640 CLINICALLY TO TREAT MYOFASCIAL 255 00:11:08,640 --> 00:11:08,840 PAIN. 256 00:11:08,840 --> 00:11:11,880 THE FIRST SET OF APPLICATIONS WE 257 00:11:11,880 --> 00:11:18,160 FUNDED INCLUDED ULTRASOUND, MRI, 258 00:11:18,160 --> 00:11:28,680 INCLUDING ELASTOGRAPHY AND EMG 259 00:11:33,760 --> 00:11:37,040 AND SPECTROSCOPY AND LOOKING AT 260 00:11:37,040 --> 00:11:39,920 VARIOUS PARTS OF THE BODY, BACK, 261 00:11:39,920 --> 00:11:41,040 NECK, SHOULDER, ETCETERA. 262 00:11:41,040 --> 00:11:44,720 THE KINDS OF MANIPULATION PEOPLE 263 00:11:44,720 --> 00:11:48,320 WILL BE USING INCLUDING 264 00:11:48,320 --> 00:11:49,960 DIFFERENT TYPES OF INJECTIONS 265 00:11:49,960 --> 00:11:53,800 AND DRY NEEDLING, ACUPUNCTURE 266 00:11:53,800 --> 00:11:54,720 AND MANIPULATION AND DIFFERENT 267 00:11:54,720 --> 00:11:55,680 TYPES OF THERAPY. 268 00:11:55,680 --> 00:11:58,080 YOU CAN SEE THERE WAS A VARIETY 269 00:11:58,080 --> 00:12:01,680 BUT WE FEEL BASED ON THE 270 00:12:01,680 --> 00:12:04,080 RESPONSE WE GOT FOR THE FIRST 271 00:12:04,080 --> 00:12:09,200 RFA THERE'S A LOT MORE OUT THERE 272 00:12:09,200 --> 00:12:13,280 BEING MORE SCIENTISTS WHO COULD 273 00:12:13,280 --> 00:12:14,040 COMPETE IN ANOTHER OPPORTUNITY 274 00:12:14,040 --> 00:12:14,640 AND THIS IS WHAT WE'RE DOING 275 00:12:14,640 --> 00:12:17,480 NOW. 276 00:12:17,480 --> 00:12:20,320 SO WE REISSUED THIS REQUEST FOR 277 00:12:20,320 --> 00:12:20,600 APPLICATION. 278 00:12:20,600 --> 00:12:21,840 IT CAME OUT IN EARLY JUNE AND 279 00:12:21,840 --> 00:12:23,800 THE DEADLINE FOR SUBMITTING 280 00:12:23,800 --> 00:12:26,760 APPLICATIONS IS OCTOBER 18 -- 281 00:12:26,760 --> 00:12:29,320 >>AND THAT'S 2023, 282 00:12:29,320 --> 00:12:31,360 DR. LANGEVIN. 283 00:12:31,360 --> 00:12:32,520 >>THAT'S A TYPO. 284 00:12:32,520 --> 00:12:36,640 SO 2023, THANK YOU, ALEX. 285 00:12:36,640 --> 00:12:42,200 SO, YEAH, THE DEADLINE IS NOT 286 00:12:42,200 --> 00:12:43,640 OVER. 287 00:12:43,640 --> 00:12:46,320 SO WE WANT TO IN THIS TECHNICAL 288 00:12:46,320 --> 00:12:46,960 ASSISTANCE WEBINAR TO GIVE YOU 289 00:12:46,960 --> 00:12:47,840 MORE INFORMATION ABOUT THE 290 00:12:47,840 --> 00:12:49,640 PROCESS OF SUBMITTING THE 291 00:12:49,640 --> 00:12:51,800 APPLICATIONS, WHAT IS EXPECTED, 292 00:12:51,800 --> 00:12:54,960 WHAT WOULD BE SOME OF THE 293 00:12:54,960 --> 00:12:59,000 MILESTONES, ETCETERA AND ALSO 294 00:12:59,000 --> 00:13:00,800 VERY IMPORTANTLY AS WAS THE CASE 295 00:13:00,800 --> 00:13:05,280 FOR THE FIRST RFA, WE WANT TO 296 00:13:05,280 --> 00:13:09,760 MAKE SURE PEOPLE FORM TEAMS OF 297 00:13:09,760 --> 00:13:13,280 COLLABORATORS THAT WOULD INCLUDE 298 00:13:13,280 --> 00:13:13,920 CLINICIANS ENGAGED IN THE 299 00:13:13,920 --> 00:13:15,640 TREATMENT OF MYOFASCIAL PAIN AND 300 00:13:15,640 --> 00:13:19,400 CAN GUIDE THE DESIGN OF THE 301 00:13:19,400 --> 00:13:20,280 STUDIES AS WELL AS ENGINEERS, 302 00:13:20,280 --> 00:13:23,760 TOOL DEVELOPERS, IMAGEERS AND 303 00:13:23,760 --> 00:13:26,920 PEOPLE USED TO HANDLING COMPLEX 304 00:13:26,920 --> 00:13:29,320 DATA AND SO THIS IS BASICALLY 305 00:13:29,320 --> 00:13:31,400 WHAT WE ARE GOING TO BE TALKING 306 00:13:31,400 --> 00:13:32,280 ABOUT FOR THE NEXT REST OF THE 307 00:13:32,280 --> 00:13:42,440 WEBINAR. 308 00:13:42,960 --> 00:13:43,360 >>AWESOME. 309 00:13:43,360 --> 00:13:45,280 THANK YOU FOR LAYING THE STAGE, 310 00:13:45,280 --> 00:13:46,320 DR. LANGEVIN. 311 00:13:46,320 --> 00:13:52,520 THE NEXT SPEAKER IS DR. ALEX 312 00:13:52,520 --> 00:13:52,760 TUTTLE. 313 00:13:52,760 --> 00:13:55,560 >>THANK YOU, FOR SETTING THE 314 00:13:55,560 --> 00:13:57,960 OVER ALL SCOPE AND IMPACT OF 315 00:13:57,960 --> 00:14:02,520 BOTH THE FIRST PAY PLAN AND THE 316 00:14:02,520 --> 00:14:04,000 CALL FOR THE REISSUE. 317 00:14:04,000 --> 00:14:07,320 CAN EVERYONE SEE MY SCREEN? 318 00:14:07,320 --> 00:14:07,480 YES? 319 00:14:07,480 --> 00:14:07,680 OKAY. 320 00:14:07,680 --> 00:14:09,320 I'M GETTING NODS. 321 00:14:09,320 --> 00:14:10,120 THANK YOU. 322 00:14:10,120 --> 00:14:11,840 I'LL FIRST GIVE A BRIEF OUTLINE 323 00:14:11,840 --> 00:14:13,280 OF THE TOPICS WE'LL COVER TODAY 324 00:14:13,280 --> 00:14:15,280 FOR THE REST OF THE SPEAKING 325 00:14:15,280 --> 00:14:16,400 PORTION BEFORE WE GET TO YOUR 326 00:14:16,400 --> 00:14:17,680 QUESTION AND ANSWER SESSION. 327 00:14:17,680 --> 00:14:22,880 I'LL START WITH AN INTRODUCTION 328 00:14:22,880 --> 00:14:26,720 OF THE NOFO AND THE 329 00:14:26,720 --> 00:14:28,160 PARTICIPATING INSTITUTE, CENTERS 330 00:14:28,160 --> 00:14:30,520 AND OFFICES TAKING PART IN THE 331 00:14:30,520 --> 00:14:30,760 REISSUE. 332 00:14:30,760 --> 00:14:32,160 I'LL THROUGH THE SPECIFIC 333 00:14:32,160 --> 00:14:35,080 PROGRAM REQUIREMENTS, THE RFA 334 00:14:35,080 --> 00:14:36,800 SCOPE AND PRIORITIES TO HELP YOU 335 00:14:36,800 --> 00:14:40,200 WHAT YOU NEED TO WRITE IN YOUR 336 00:14:40,200 --> 00:14:40,880 APPLICATION IN THE RESPONSE TO 337 00:14:40,880 --> 00:14:44,720 THE NOTICE OF FUNDING 338 00:14:44,720 --> 00:14:55,400 OPPORTUNITY OR NOFO AND THERE 339 00:14:55,400 --> 00:14:57,320 WILL BE A TEAMING WEBINAR 340 00:14:57,320 --> 00:14:59,880 BECAUSE THESE ARE TEAM-BASED 341 00:14:59,880 --> 00:15:00,720 SCIENTIFIC PROJECTS AND WE'RE 342 00:15:00,720 --> 00:15:02,720 GIVING EVERYONE AN OPPORTUNITY 343 00:15:02,720 --> 00:15:07,360 TO NETWORK AND MAYBE DEVELOP 344 00:15:07,360 --> 00:15:07,920 COLLABORATIONS BETWEEN THE 345 00:15:07,920 --> 00:15:10,360 OCTOBER 18 DEADLINE. 346 00:15:10,360 --> 00:15:12,400 WE HOPE TO SAVE ABOUT HALF AN 347 00:15:12,400 --> 00:15:13,760 HOUR FOR QUESTIONS. 348 00:15:13,760 --> 00:15:16,520 SUBMIT THEM THROUGH THE NIH 349 00:15:16,520 --> 00:15:17,280 VIDEOCAST FEEDBACK FORM ANY TIME 350 00:15:17,280 --> 00:15:20,360 DURING THE WEB DMAR. 351 00:15:20,360 --> 00:15:22,840 -- WEBINAR. 352 00:15:22,840 --> 00:15:24,640 THE IDEA FOR BOTH ORIGINAL ISSUE 353 00:15:24,640 --> 00:15:28,280 OF THIS RFA AND REISSUE WE'RE 354 00:15:28,280 --> 00:15:29,720 DISCUSSING TODAY CAME ABOUT FROM 355 00:15:29,720 --> 00:15:32,720 THE 2020 HEAL WORKSHOP ON 356 00:15:32,720 --> 00:15:33,360 MYOFASCIAL PAIN. 357 00:15:33,360 --> 00:15:34,280 IF YOU WOULD LIKE MORE 358 00:15:34,280 --> 00:15:38,080 INFORMATION ABOUT THAT WEBINAR, 359 00:15:38,080 --> 00:15:39,640 THERE ARE LINKS TO THE VIDEO 360 00:15:39,640 --> 00:15:40,680 RECORDINGS AND EXECUTIVE SUMMARY 361 00:15:40,680 --> 00:15:43,560 AND DETAILED SUMMARIES OF THE 362 00:15:43,560 --> 00:15:44,680 TWO-DAY WORKSHOP EMBEDDED IN THE 363 00:15:44,680 --> 00:15:46,480 NOTICE OF THE FUNDING 364 00:15:46,480 --> 00:15:48,200 OPPORTUNITY FOR REISSUE. 365 00:15:48,200 --> 00:15:51,520 FIND THE LINKS AND YOU MAY FIND 366 00:15:51,520 --> 00:15:53,280 COLLABORATORS AMONG THE 367 00:15:53,280 --> 00:15:54,200 COLLABORATORS THAT PARTICIPATED 368 00:15:54,200 --> 00:15:56,240 IN THE WORKSHOP. 369 00:15:56,240 --> 00:16:06,760 THE WORKSHOP AND NOFFO -- NOFO 370 00:16:10,240 --> 00:16:13,320 WAS A COLLABORATION AND WE HAVE 371 00:16:13,320 --> 00:16:16,320 SEVEN OTHER I.C.s PARTICIPATING 372 00:16:16,320 --> 00:16:18,840 IN THE REISSUE AND THESE ARE THE 373 00:16:18,840 --> 00:16:20,480 PARTICIPATING CONTACTS. 374 00:16:20,480 --> 00:16:28,240 YOU MAY HAVE HEARD ABOUT THE 375 00:16:28,240 --> 00:16:29,760 OPPORTUNITY FROM AN OFFICER AND 376 00:16:29,760 --> 00:16:31,120 MAYBE THIS ALIGNS WITH THE 377 00:16:31,120 --> 00:16:32,400 RESEARCH YOU TYPICALLY DO BUT 378 00:16:32,400 --> 00:16:33,640 ANY OF US WOULD BE HAPPY TO 379 00:16:33,640 --> 00:16:34,840 ANSWER YOUR QUESTIONS AND TRY TO 380 00:16:34,840 --> 00:16:44,200 RESPOND AS SOON AS POSSIBLE. 381 00:16:44,200 --> 00:16:47,800 THE MYOFASCIAL UNIT IS 382 00:16:47,800 --> 00:16:48,400 CONNECTIVE TISSUES AND BLOOD 383 00:16:48,400 --> 00:16:52,120 VESSELS AND LYMPHATICS. 384 00:16:52,120 --> 00:16:54,400 THE PARIETAL FASCIA CHANGES IN 385 00:16:54,400 --> 00:16:56,720 RESPONSE TO INFLAMMATION. 386 00:16:56,720 --> 00:16:57,960 THERE'S OTHER POSSIBLE 387 00:16:57,960 --> 00:16:59,240 PATHOLOGICAL CHANGES THAT COULD 388 00:16:59,240 --> 00:17:02,720 BE ASSOCIATED INCLUDING 389 00:17:02,720 --> 00:17:05,720 FIBROSIS, FATTY INFILTRATION, 390 00:17:05,720 --> 00:17:11,120 MUSCLE HYPEREXTENDABILITY OR 391 00:17:11,120 --> 00:17:14,560 ISCHEMIA AND MANY HAVE BEEN 392 00:17:14,560 --> 00:17:17,560 IMPLICATED IN MANY PAINFUL 393 00:17:17,560 --> 00:17:23,560 CONDITIONS INCLUDING HEADACHE, 394 00:17:23,560 --> 00:17:24,440 TMJ, SICKLE CELL DISEASE AND 395 00:17:24,440 --> 00:17:25,520 PAIN DISORDERS IN SPECIAL PAIN 396 00:17:25,520 --> 00:17:28,880 POPULATIONS. 397 00:17:28,880 --> 00:17:30,520 THE KEY RESEARCH ISSUE IN THE 398 00:17:30,520 --> 00:17:32,720 REISSUE THAT WE'RE PRESENTING 399 00:17:32,720 --> 00:17:34,680 TODAY IS TO LEVERAGE EXISTING OR 400 00:17:34,680 --> 00:17:36,720 DEVELOP NEW QUANTITATIVE AND 401 00:17:36,720 --> 00:17:38,320 MINIMALLY INVASIVE TECHNOLOGIES 402 00:17:38,320 --> 00:17:41,600 TO HELP US DIFFERENTIATE BETWEEN 403 00:17:41,600 --> 00:17:46,800 HEALTHY AND DISEASED 404 00:17:46,800 --> 00:17:47,800 MYOFASCIAL--AND THE LATENT STAGE 405 00:17:47,800 --> 00:17:50,440 WHERE THERE'S NO SPONTANEOUS 406 00:17:50,440 --> 00:17:53,120 PAIN BUT WE CAN OBSERVE 407 00:17:53,120 --> 00:17:53,720 PATHOLOGICAL CHANGES IN THE 408 00:17:53,720 --> 00:17:55,160 MYOFASCIAL UNIT WHEN PRESSED AND 409 00:17:55,160 --> 00:17:57,280 THE ACTIVE STAGE WHERE A PERSON 410 00:17:57,280 --> 00:18:01,160 EXPERIENCES SEVERE PAIN 411 00:18:01,160 --> 00:18:03,640 SPONTANEOUSLY WITH OBSERVABLE 412 00:18:03,640 --> 00:18:04,240 PATHOLOGICAL CHANGES IN THE 413 00:18:04,240 --> 00:18:04,800 MYOFASCIAL UNIT. 414 00:18:04,800 --> 00:18:06,240 AS DISCUSSED IN THE HEAL 415 00:18:06,240 --> 00:18:09,280 WORKSHOP IN 2020, THERE ARE MANY 416 00:18:09,280 --> 00:18:10,320 CUTTING EDGE TECHNOLOGIES 417 00:18:10,320 --> 00:18:12,200 AVAILABLE THAT COULD BE USED TO 418 00:18:12,200 --> 00:18:14,920 DEVELOP QUANTITATIVE MEASURES TO 419 00:18:14,920 --> 00:18:17,320 DIFFERENTIATE DISEASE FROM 420 00:18:17,320 --> 00:18:19,320 HEALTHY TISSUE STATES AND THEY 421 00:18:19,320 --> 00:18:21,520 CAN SERVE AS CANDIDATE 422 00:18:21,520 --> 00:18:24,360 INDICATORS OR BIOMARKERS IN A 423 00:18:24,360 --> 00:18:26,760 FUTURE GRANT OR PROJECT THAT CAN 424 00:18:26,760 --> 00:18:27,760 HELP DIFFERENTIATE DISEASE FROM 425 00:18:27,760 --> 00:18:29,760 HEALTHY MYOFASCIAL UNITS. 426 00:18:29,760 --> 00:18:31,000 SOME EXAMPLES OF THE 427 00:18:31,000 --> 00:18:32,720 TECHNOLOGIES DISCUSSED AT THE 428 00:18:32,720 --> 00:18:37,840 2020 WORKSHOP WERE MR 429 00:18:37,840 --> 00:18:39,320 ELASTOGRAPHY AND TISSUE 430 00:18:39,320 --> 00:18:41,280 PROFUSION, LASER DOPPLER IMAGING 431 00:18:41,280 --> 00:18:43,440 OR MODELLING AND SIMULATIONS. 432 00:18:43,440 --> 00:18:45,080 AND IT'S IMPORTANT TO NOTE THAT 433 00:18:45,080 --> 00:18:47,840 AS DR. LANGEVIN SHOWED A MINUTE 434 00:18:47,840 --> 00:18:52,800 AGO, MANY APPLICATIONS THAT 435 00:18:52,800 --> 00:18:55,360 FUNDED WERE USING 436 00:18:55,360 --> 00:18:56,120 MULTIPARAMETRIC MODALITIES TO 437 00:18:56,120 --> 00:18:59,960 ARRIVE AT COMPOSITE OR PARALLEL 438 00:18:59,960 --> 00:19:00,600 QUANTITATIVE MEASURES OF THE 439 00:19:00,600 --> 00:19:01,160 MYOFASCIAL UNIT. 440 00:19:01,160 --> 00:19:03,480 SO WE DO WANT TO IMPRESS UPON 441 00:19:03,480 --> 00:19:04,680 YOU YOU ARE WELCOME TO LEVERAGE 442 00:19:04,680 --> 00:19:07,000 MORE THAN ONE OF THESE 443 00:19:07,000 --> 00:19:08,760 TECHNOLOGIES MAYBE CONCURRENTLY 444 00:19:08,760 --> 00:19:13,240 TO STUDY THE MYOFASCIAL UNIT. 445 00:19:13,240 --> 00:19:16,840 I WANTED TO PULL OUT SPECIFIC 446 00:19:16,840 --> 00:19:18,480 APPROACHES WE'RE STRESSING FOR 447 00:19:18,480 --> 00:19:19,920 THE REISSUE. 448 00:19:19,920 --> 00:19:21,120 THESE ARE OF PARTICULAR INTEREST 449 00:19:21,120 --> 00:19:23,080 US TO THIS TIME AROUND. 450 00:19:23,080 --> 00:19:24,760 IT'S IMPORTANT TO MENTION NO 451 00:19:24,760 --> 00:19:26,040 PRELIMINARY DATA ARE REQUIRED 452 00:19:26,040 --> 00:19:29,040 AND I'LL GET TO THE R61 VERSUS 453 00:19:29,040 --> 00:19:31,240 THE R33 PHASE IN A MOMENT AND 454 00:19:31,240 --> 00:19:33,280 FEASIBILITY MAY BE DEMONSTRATED 455 00:19:33,280 --> 00:19:34,360 THROUGH LITERATURE CITATIONS OR 456 00:19:34,360 --> 00:19:36,960 DATA YOU MAY HAVE GENERATED IN 457 00:19:36,960 --> 00:19:38,440 ANIMAL STUDIES OR HUMAN SUBJECT 458 00:19:38,440 --> 00:19:39,760 STUDIES YOU PREVIOUSLY 459 00:19:39,760 --> 00:19:40,320 CONDUCTED. 460 00:19:40,320 --> 00:19:41,560 YOU MAY CHOOSE ONE TYPE OF 461 00:19:41,560 --> 00:19:42,920 TECHNOLOGY OR MULTIPLE 462 00:19:42,920 --> 00:19:44,440 TECHNOLOGIES DESCRIBED ABOVE TO 463 00:19:44,440 --> 00:19:47,480 DEVELOP THE QUANTITATIVE 464 00:19:47,480 --> 00:19:48,720 MEASURES TO ASSESS THE 465 00:19:48,720 --> 00:19:50,760 MYOFASCIAL UNIT AND MUSCLE AND 466 00:19:50,760 --> 00:19:55,400 CONNECTIVE TISSUE AND LYMPHATICS 467 00:19:55,400 --> 00:19:57,840 AND IT SHOULD BE DESCRIBED TO 468 00:19:57,840 --> 00:20:00,560 DISTINGUISH HEALTHY VERSUS 469 00:20:00,560 --> 00:20:02,720 DISEASED TISSUE STATES WITH A 470 00:20:02,720 --> 00:20:03,360 REASONABLE DEGREE OF FIDELITY. 471 00:20:03,360 --> 00:20:07,000 SO NOW GETTING TO THE MEAT OF 472 00:20:07,000 --> 00:20:12,320 THE TWO-PHASED AWARD OF THE RFA. 473 00:20:12,320 --> 00:20:13,480 IT REQUIRES TWO PHASES OR TWO 474 00:20:13,480 --> 00:20:15,600 TYPES OF STUDIES. 475 00:20:15,600 --> 00:20:17,280 IN THE FIRST PHASE THE R61 476 00:20:17,280 --> 00:20:19,080 PHASE, THE CANDIDATE SHOULD 477 00:20:19,080 --> 00:20:23,080 PROPOSE OBSERVATIONAL STUDIES TO 478 00:20:23,080 --> 00:20:25,280 HELP DEVELOP ANY OF THE 479 00:20:25,280 --> 00:20:26,120 TECHNOLOGIES DESCRIBED IN THE 480 00:20:26,120 --> 00:20:31,720 PREVIOUS SLIDE OR LISTED ON THIS 481 00:20:31,720 --> 00:20:39,120 SLIDE IF YOU SEE ANY OF THESE 482 00:20:39,120 --> 00:20:41,680 TECHNOLOGIES SUMMARIZED IN THE 483 00:20:41,680 --> 00:20:43,520 RFA TO ASSESS IN HUMAN SUBJECTS 484 00:20:43,520 --> 00:20:47,600 AND SEE IF IT CAN DIFFERENTIATE 485 00:20:47,600 --> 00:20:51,640 AMONG DISEASED AND HEALTHY 486 00:20:51,640 --> 00:20:52,440 MYOFASCIAL UNITS AND PLAY SELECT 487 00:20:52,440 --> 00:20:54,000 A POPULATION WITH A CERTAIN TYPE 488 00:20:54,000 --> 00:20:57,280 OF PAIN SUCH AS POPULATIONS WHO 489 00:20:57,280 --> 00:21:05,680 EXPERIENCE HEADACHE, TEMPORAL 490 00:21:05,680 --> 00:21:07,520 MANDIBULAR DISORDER, NECK, ARM, 491 00:21:07,520 --> 00:21:10,520 LEG OR PELVIC PAIN OR A 492 00:21:10,520 --> 00:21:12,440 JUSTIFIABLE PAIN CONDITION IN 493 00:21:12,440 --> 00:21:13,480 CERTAIN POPULATIONS DENOTED IN 494 00:21:13,480 --> 00:21:16,560 THE SPECIFIC RFA. 495 00:21:16,560 --> 00:21:18,840 I WANT TO EMPHASIZE YOU MUST 496 00:21:18,840 --> 00:21:20,760 INCLUDE A BRIEF PLAN IN THE R61 497 00:21:20,760 --> 00:21:24,200 PHASE HOW TO EXTEND YOUR 498 00:21:24,200 --> 00:21:25,840 INVESTIGATOR TEAM WITH 499 00:21:25,840 --> 00:21:26,960 ADDITIONAL EXPERTISE AND 500 00:21:26,960 --> 00:21:30,240 INTERVENTIONS IF YOUR RFA IS NOT 501 00:21:30,240 --> 00:21:32,680 ABLE TO IDENTIFY SPECIFIC 502 00:21:32,680 --> 00:21:33,280 COLLABORATORS DURING YOUR 503 00:21:33,280 --> 00:21:34,080 COLLABORATION PREPARATION 504 00:21:34,080 --> 00:21:34,320 PROCESS. 505 00:21:34,320 --> 00:21:36,080 WE'RE NOT ASKING FOR IT TO BE 506 00:21:36,080 --> 00:21:38,440 FULLY DEVELOPED BUT NEED TO 507 00:21:38,440 --> 00:21:40,320 SPECIFY A PLAN BY WHICH YOU'LL 508 00:21:40,320 --> 00:21:45,320 BUILD A CLINICAL TEAM TO PERTURB 509 00:21:45,320 --> 00:21:48,560 THE MEASURES YOU'RE STUDYING TO 510 00:21:48,560 --> 00:21:51,240 LOOK FOR CHANGES IN THE 511 00:21:51,240 --> 00:21:53,280 MYOFASCIAL UNIT AND MUST ALSO 512 00:21:53,280 --> 00:21:56,760 INDICATE YOU'LL COMPLETE THE 513 00:21:56,760 --> 00:22:00,360 CLINICAL STUDY PROTOCOL AS PART 514 00:22:00,360 --> 00:22:01,280 OF THE DESCRIPTION. 515 00:22:01,280 --> 00:22:03,800 IN THE APPLICATION, SPECIFIC 516 00:22:03,800 --> 00:22:05,400 AIMS PAGE AS WELL AS YOUR 517 00:22:05,400 --> 00:22:06,480 RESEARCH STRATEGY SECTION, TWO 518 00:22:06,480 --> 00:22:09,280 SEPARATE SECTIONS YOU'LL BE 519 00:22:09,280 --> 00:22:11,680 WRITING, YOU'LL NEED TO INCLUDE 520 00:22:11,680 --> 00:22:14,760 THE R61 TO R33 CRITERIA. 521 00:22:14,760 --> 00:22:16,440 INCLUDE QUANTITATIVE MILESTONES 522 00:22:16,440 --> 00:22:25,600 TO SPECIFY THE THRESHOLDS YOU'LL 523 00:22:25,600 --> 00:22:26,000 USI 524 00:22:26,000 --> 00:22:26,200 USING. 525 00:22:26,200 --> 00:22:28,320 IF MULTIPLE THRESHOLDS ARE 526 00:22:28,320 --> 00:22:29,280 PROPOSED PRIORITIZATION SHOULD 527 00:22:29,280 --> 00:22:30,840 BE PROVIDED TO DETERMINE WHICH 528 00:22:30,840 --> 00:22:33,160 MEASURES WOULD BE MOVED FORWARD 529 00:22:33,160 --> 00:22:35,360 TO THE R33 PHASE FOR BIOMARKER 530 00:22:35,360 --> 00:22:35,640 DEVELOPMENT. 531 00:22:35,640 --> 00:22:36,920 IF YOU'RE DOING MULTIPLE 532 00:22:36,920 --> 00:22:38,160 MEASURES YOU NEED TO PRIORITIZE 533 00:22:38,160 --> 00:22:39,840 WHICH ONES DO YOU EXPECT TO GO 534 00:22:39,840 --> 00:22:42,720 TO THE R33 PHASE. 535 00:22:42,720 --> 00:22:43,440 ALTERNATIVELY, IF THE THRESHOLD 536 00:22:43,440 --> 00:22:45,520 OF THE COMPOSITE MEASURE IF YOU 537 00:22:45,520 --> 00:22:48,880 DECIDE TO USE A COMPOSITE 538 00:22:48,880 --> 00:22:50,760 MEASURE OR THRESHOLD OF THE 539 00:22:50,760 --> 00:22:51,520 MEASURE AMONG MULTIPLE 540 00:22:51,520 --> 00:22:55,120 TECHNOLOGIES YOU MUST PROPOSED 541 00:22:55,120 --> 00:23:00,000 THE R33 PHASE IF ARE DOING 542 00:23:00,000 --> 00:23:01,320 MULTIDIMENSIONAL IN THE R61 543 00:23:01,320 --> 00:23:04,200 PHASE AND MILESTONES MUST 544 00:23:04,200 --> 00:23:06,600 INCLUDE THRESHOLDS AND PREFERRED 545 00:23:06,600 --> 00:23:09,240 METRICS ARE EFFECT SIZES SUCH AS 546 00:23:09,240 --> 00:23:12,680 GREATER THAN .5 AND AVERAGE AREA 547 00:23:12,680 --> 00:23:13,560 UNDER THE CURVE FOR EXAMPLE FOR 548 00:23:13,560 --> 00:23:17,000 ROC OF . OR OTHER METRICS OF 549 00:23:17,000 --> 00:23:20,520 CLASSIFICATION ACCURACY SUCH AS 550 00:23:20,520 --> 00:23:22,320 SENSITIVITY AND SPECIFICITY 551 00:23:22,320 --> 00:23:24,160 METRICS IF YOU'RE TARGETING A.I. 552 00:23:24,160 --> 00:23:26,200 TARGETED FOR 70% ACCURACY. 553 00:23:26,200 --> 00:23:29,920 INCLUDE THE TIME LINE -- SORRY. 554 00:23:29,920 --> 00:23:33,160 IF YOU'RE REQUESTING THE TWO OR 555 00:23:33,160 --> 00:23:35,680 THREE-YEAR R61 PHASE YOU CAN 556 00:23:35,680 --> 00:23:38,440 CHOOSE, FINISH BY MONTH 32. 557 00:23:38,440 --> 00:23:41,000 IF THE FULL THREE R61 PHASE YOU 558 00:23:41,000 --> 00:23:42,840 NEED TO HAVE YOUR EXPERIMENTS 559 00:23:42,840 --> 00:23:46,400 DONE BY MONTH 32 AFTER THE AWARD 560 00:23:46,400 --> 00:23:48,880 TO REQUEST A TRANSITION TO THE 561 00:23:48,880 --> 00:23:49,280 NEXT PHASE. 562 00:23:49,280 --> 00:23:51,440 WE NEED A RUN OF THREE OR FOUR 563 00:23:51,440 --> 00:23:53,120 MONTHS TO RECEIVE ALL THE 564 00:23:53,120 --> 00:23:54,400 MATERIALS FOR TRANSITION TO THE 565 00:23:54,400 --> 00:23:55,040 R33 AND REVIEW THOSE INTERNALLY. 566 00:23:55,040 --> 00:23:57,960 BEFORE I GET TO THE R33 PHASE, 567 00:23:57,960 --> 00:24:01,120 THERE ARE MANY EXISTING 568 00:24:01,120 --> 00:24:03,240 TREATMENTS USED TO STUDY 569 00:24:03,240 --> 00:24:04,640 MYOFASCIAL PAIN AND FEW 570 00:24:04,640 --> 00:24:05,880 INTERVENTIONS OR TREATMENTS HAVE 571 00:24:05,880 --> 00:24:08,080 SUFFICIENT ACCURACY OR 572 00:24:08,080 --> 00:24:08,600 MECHANISTIC EVIDENCE. 573 00:24:08,600 --> 00:24:10,520 PART OF THE GOAL OF THIS NOTICE 574 00:24:10,520 --> 00:24:14,280 OF FUNDING OPPORTUNITY IS TO USE 575 00:24:14,280 --> 00:24:17,160 AND FURTHER DEVELOP THE 576 00:24:17,160 --> 00:24:18,200 INTERVENTIONS TO PERTURB THE 577 00:24:18,200 --> 00:24:20,600 MYOFASCIAL UNIT TO SEE HOW THE 578 00:24:20,600 --> 00:24:21,360 INTERVENTIONS CAN CHANGE THE 579 00:24:21,360 --> 00:24:23,240 GROUND STATE YOU'RE DEVELOPING 580 00:24:23,240 --> 00:24:26,640 IN YOUR QUANTITATIVE MEASURE OR 581 00:24:26,640 --> 00:24:27,240 THRESHOLD IN THE INITIAL R61 582 00:24:27,240 --> 00:24:30,080 PHASE. 583 00:24:30,080 --> 00:24:33,880 SO FOR THE R33 PHASE YOU MUST 584 00:24:33,880 --> 00:24:34,880 CHOOSE ONE OR MORE OF THE 585 00:24:34,880 --> 00:24:36,280 FOLLOWING TREATMENTS AND 586 00:24:36,280 --> 00:24:37,680 THERAPIES AND THE APPROPRIATE 587 00:24:37,680 --> 00:24:39,520 CONTROL GROUP TO DESIGN THE 588 00:24:39,520 --> 00:24:41,120 RANDOMIZED CONTROL TRIAL. 589 00:24:41,120 --> 00:24:43,560 IT MAY BE A MANIPULATION 590 00:24:43,560 --> 00:24:46,680 INCLUDING MANUAL THERAPIES OR 591 00:24:46,680 --> 00:24:48,600 STRETCHING-BASED THERAPIES, DRY 592 00:24:48,600 --> 00:24:50,520 NEEDLING OR ACUPUNCTURE, 593 00:24:50,520 --> 00:24:53,120 TARGETED INJECTION THERAPIES 594 00:24:53,120 --> 00:24:56,600 SUCH AS LIDOCAINE AND OTHER 595 00:24:56,600 --> 00:24:57,120 MANIPULATIONS. 596 00:24:57,120 --> 00:24:58,720 IF YOU CHOOSE OTHER ANOTHER NOT 597 00:24:58,720 --> 00:25:00,280 LISTED IN THE FIVE BULLET POINTS 598 00:25:00,280 --> 00:25:01,440 THE APPLICATION SHOULD DESCRIBE 599 00:25:01,440 --> 00:25:03,160 EVIDENCE SUPPORTING DEVELOPMENT 600 00:25:03,160 --> 00:25:04,640 OF THAT INTERVENTION'S AFFECT ON 601 00:25:04,640 --> 00:25:08,080 THE MYOFASCIAL UNIT AND HOW THE 602 00:25:08,080 --> 00:25:09,920 CHOSEN THERAPY WILL PRODUCE 603 00:25:09,920 --> 00:25:13,760 CHANGES TO BE MEASURED USING THE 604 00:25:13,760 --> 00:25:14,720 QUANTITATIVE ASSESSMENT IN THE 605 00:25:14,720 --> 00:25:18,520 R31 PHASE. 606 00:25:18,520 --> 00:25:26,080 YOU ALSO NEED TO TEST THE YOU 607 00:25:26,080 --> 00:25:28,400 NEED TO TEST OR PERFORM AN 608 00:25:28,400 --> 00:25:29,680 APPROPRIATE CLINICAL PAIN 609 00:25:29,680 --> 00:25:31,320 ASSESSMENT AT BASELINE AND AT 610 00:25:31,320 --> 00:25:33,360 THE END OF THE INTERVENTION 611 00:25:33,360 --> 00:25:35,360 ASSESS THE QUANTITATIVE MEASURE 612 00:25:35,360 --> 00:25:38,360 TO PREDICT OUTCOMES OF THE 613 00:25:38,360 --> 00:25:38,680 INTERVENTION. 614 00:25:38,680 --> 00:25:41,120 WE NEED CLINICAL VERIFICATION OF 615 00:25:41,120 --> 00:25:42,160 THE MYOFASCIAL UNITS INVOLVED IN 616 00:25:42,160 --> 00:25:46,120 WHAT YOU'RE MEASURING. 617 00:25:46,120 --> 00:25:49,320 THIRDLY, YOU SHOULD PROPOSE TO 618 00:25:49,320 --> 00:25:54,360 PERFORM A CLINICAL PAIN 619 00:25:54,360 --> 00:25:55,960 ASSESSMENT -- SORRY. 620 00:25:55,960 --> 00:25:57,480 I'M MISSING A BULLET POINT. 621 00:25:57,480 --> 00:26:02,160 AND YOU SHOULD PROPOSE TO 622 00:26:02,160 --> 00:26:04,800 PERFORM AN ASSESSMENT OR 623 00:26:04,800 --> 00:26:07,520 CALCULATE THE SENSITIVITY AND 624 00:26:07,520 --> 00:26:09,000 SPECIFICITY OF THE R61 AND 625 00:26:09,000 --> 00:26:12,320 MONITOR THE TREATMENT RESPONSE 626 00:26:12,320 --> 00:26:13,880 AND PREDICT CLINICAL OUTCOMES. 627 00:26:13,880 --> 00:26:16,800 A PLAN SHOULD BE INCLUDED IN THE 628 00:26:16,800 --> 00:26:18,320 R33. 629 00:26:18,320 --> 00:26:20,600 DESPITE THE MANY REQUIREMENTS OF 630 00:26:20,600 --> 00:26:22,280 THE PHASE WE WANT TO STRESS TO 631 00:26:22,280 --> 00:26:24,880 APPLICANTS YOU SHOULD BE BRIEF 632 00:26:24,880 --> 00:26:25,560 IN DESCRIBING THIS PORTION OF 633 00:26:25,560 --> 00:26:29,160 THE PROPOSAL AS THE R33 DESIGN 634 00:26:29,160 --> 00:26:31,560 MAY BE MODIFIED AT THE TIME OF 635 00:26:31,560 --> 00:26:32,000 TRANSITION. 636 00:26:32,000 --> 00:26:33,600 WHEN YOU REQUEST A TRANSITION 637 00:26:33,600 --> 00:26:39,240 FROM THE R61 TO R33 YOU'LL HAVE 638 00:26:39,240 --> 00:26:40,760 TIME TO NEGOTIATE OR PROVIDE A 639 00:26:40,760 --> 00:26:43,440 MORE COMPLETE PICTURE OF YOUR 640 00:26:43,440 --> 00:26:44,640 R33 STUDY. 641 00:26:44,640 --> 00:26:49,120 ALSO REMEMBER TO COMPLETE THE 642 00:26:49,120 --> 00:26:51,120 HUMAN SUBJECTS IN CLINICAL TRIAL 643 00:26:51,120 --> 00:26:52,360 INFORMATION FORM FOR YOUR 644 00:26:52,360 --> 00:26:53,040 INITIAL APPLICATION. 645 00:26:53,040 --> 00:26:55,480 BOTH THE R33, R61 AND TRANSITION 646 00:26:55,480 --> 00:26:58,000 ARE ALL EVALUATED DURING REVIEW. 647 00:26:58,000 --> 00:26:59,120 GOOD HUANG WILL GO IN MORE 648 00:26:59,120 --> 00:27:03,640 DETAIL ABOUT THAT. 649 00:27:03,640 --> 00:27:04,840 FOLLOWING HEAL DATA RESOURCE 650 00:27:04,840 --> 00:27:05,560 SHARING POLICY. 651 00:27:05,560 --> 00:27:08,000 I ENCOURAGE YOU TO REVIEW THE 652 00:27:08,000 --> 00:27:10,000 LINKS AS YOU PREPARE SINCE IT'S 653 00:27:10,000 --> 00:27:12,560 NEEDED IN YOUR APPLICATION. 654 00:27:12,560 --> 00:27:13,840 THE LINKS ARE ALSO IN THE NOTICE 655 00:27:13,840 --> 00:27:15,240 OF FUNDING OPPORTUNITY. 656 00:27:15,240 --> 00:27:16,680 PLEASE REMEMBER THAT THE SCOPE 657 00:27:16,680 --> 00:27:23,680 OF THIS RFA PRECLUDES ANIMAL 658 00:27:23,680 --> 00:27:24,880 MODEL STUDIES AND THE 659 00:27:24,880 --> 00:27:26,600 APPLICATION MUST INCLUDE 660 00:27:26,600 --> 00:27:30,040 QUANTITATIVE S OF AT LEAST ONE 661 00:27:30,040 --> 00:27:32,320 COMPONENT OF THE MYOFASCIAL UNIT 662 00:27:32,320 --> 00:27:33,360 IN THE DEVELOPMENT OF 663 00:27:33,360 --> 00:27:37,680 QUANTITATIVE THRESHOLDS AND 664 00:27:37,680 --> 00:27:39,360 MEASURES AND THE R33 PHASE OF 665 00:27:39,360 --> 00:27:42,080 THE SYSTEM AND USE MINIMALLY OR 666 00:27:42,080 --> 00:27:43,080 NON-INVASIVE TECHNOLOGIES 667 00:27:43,080 --> 00:27:45,160 OTHERWISE THE APPLICATION IS 668 00:27:45,160 --> 00:27:49,440 DEEMED NON RESPONSIVE AND AN 669 00:27:49,440 --> 00:27:52,560 APPLICATION THAT FAILS TO HAVE 670 00:27:52,560 --> 00:27:54,480 THE PHASE DESCRIPTION OR DOES 671 00:27:54,480 --> 00:27:57,680 NOT INCLUDE AN R33 SECTION AT 672 00:27:57,680 --> 00:27:59,560 ALL WOULD BE DEEMED NOT 673 00:27:59,560 --> 00:28:01,120 RESPONSIVE TO THIS NOTICE OF 674 00:28:01,120 --> 00:28:01,560 FUNDING OPPORTUNITY. 675 00:28:01,560 --> 00:28:04,080 BEFORE I HAND THINGS OVER TO 676 00:28:04,080 --> 00:28:04,320 DR. HUANG. 677 00:28:04,320 --> 00:28:07,200 THIS IS TO STIMULATE THE 678 00:28:07,200 --> 00:28:09,880 ADAPTATION OF INNOVATIVE IMAGING 679 00:28:09,880 --> 00:28:13,120 TECHNOLOGIES AND SIMILAR 680 00:28:13,120 --> 00:28:15,280 QUANTITATIVE ASSESSMENT METHODS 681 00:28:15,280 --> 00:28:18,120 TO DETERMINE HEALTHY OR DISEASED 682 00:28:18,120 --> 00:28:21,120 MYOFASCIAL UNITS IN SUBJECTS. 683 00:28:21,120 --> 00:28:23,640 STRONG APPLICATIONS NEED A WELL 684 00:28:23,640 --> 00:28:25,920 CONCEIVED PLAN AND R61 PHASE 685 00:28:25,920 --> 00:28:31,280 THAT LASTS UP TO THREE YEARS AND 686 00:28:31,280 --> 00:28:32,400 QUANTITATIVE ASSESSMENT METHODS. 687 00:28:32,400 --> 00:28:34,640 THE DESCRIPTION OF THE RFA PHASE 688 00:28:34,640 --> 00:28:40,040 SHOULD BE BRIEF AND DESCRIBE THE 689 00:28:40,040 --> 00:28:40,680 INTERVENTIONS IN THE CLINICAL 690 00:28:40,680 --> 00:28:41,760 PAIN POPULATION YOU'LL BE 691 00:28:41,760 --> 00:28:44,960 STUDIES TO TEST THE QUANTITATIVE 692 00:28:44,960 --> 00:28:48,520 THRESHOLDS DEVELOPED IN THE R61. 693 00:28:48,520 --> 00:28:51,880 WE'RE SOFTENING THE BIOMARKER 694 00:28:51,880 --> 00:28:54,520 TERM AND IT COULD BE A BIOMARKER 695 00:28:54,520 --> 00:28:56,480 IN THE FOLLOW-UP STUDY. 696 00:28:56,480 --> 00:28:58,200 THE RESEARCH PLAN MAY BE 697 00:28:58,200 --> 00:28:59,680 MODIFIED BASED ON THE CAUGHT 698 00:28:59,680 --> 00:29:02,640 COMES OF THE STUDY AND APPROVAL 699 00:29:02,640 --> 00:29:04,200 BY THE HEAL PROGRAM TEAM AS WE 700 00:29:04,200 --> 00:29:05,680 EVALUATE THE APPLICATION. 701 00:29:05,680 --> 00:29:08,640 ONCE AGAIN, HIGHLY INVASIVE 702 00:29:08,640 --> 00:29:09,440 TECHNOLOGIES AND BIOMARKERS WILL 703 00:29:09,440 --> 00:29:19,960 BE DEPRIORITIZED FOR THE NOFO. 704 00:29:20,360 --> 00:29:21,760 AND I'LL PASS IT TO MS. 705 00:29:21,760 --> 00:29:22,000 WILLIAMS. 706 00:29:22,000 --> 00:29:24,200 >>THE LAST SPEAKER IS 707 00:29:24,200 --> 00:29:25,480 DR. SHIYONG HUANG WITH THE 708 00:29:25,480 --> 00:29:28,160 OFFICE OF SCIENTIFIC REVIEW. 709 00:29:28,160 --> 00:29:33,680 YOU'LL HEAR THE REVIEW 710 00:29:33,680 --> 00:29:35,280 PRIORITIES AND OTHER INFORMATION 711 00:29:35,280 --> 00:29:36,080 IN THE REVIEW PROCESS. 712 00:29:36,080 --> 00:29:40,320 TAKE IT AWAY. 713 00:29:40,320 --> 00:29:42,240 >>THANK YOU. 714 00:29:42,240 --> 00:29:45,040 WE'LL NOW GO THROUGH THE 715 00:29:45,040 --> 00:29:45,560 PERSPECTIVE. 716 00:29:45,560 --> 00:29:49,600 I'LL ADDRESS THIS ASPECT OF THE 717 00:29:49,600 --> 00:29:52,040 REVIEW OF THE APPLICATIONS. 718 00:29:52,040 --> 00:29:54,000 IF AN APPLICATION IS NON 719 00:29:54,000 --> 00:29:55,440 RESPONSIVE, NON COMPLIANT OR 720 00:29:55,440 --> 00:29:59,440 INCOMPLETE IT WILL NOT BE 721 00:29:59,440 --> 00:30:01,120 ACCEPTED. 722 00:30:01,120 --> 00:30:04,960 WE WOULD LIKE TO TALK ABOUT THE 723 00:30:04,960 --> 00:30:13,120 COMPLETENESS OF THIS NOFO. 724 00:30:13,120 --> 00:30:16,520 AND WE WILL HAVE INFORMATION 725 00:30:16,520 --> 00:30:22,120 INCLUDED IN THE TIME LINES AT 726 00:30:22,120 --> 00:30:24,760 END OF MY PRESENTATION. 727 00:30:24,760 --> 00:30:25,200 IN RESPONSIVENESS. 728 00:30:25,200 --> 00:30:25,800 THE DECISION WILL BE MADE BY 729 00:30:25,800 --> 00:30:35,040 PROGRAM STAFF. 730 00:30:35,040 --> 00:30:37,400 THERE'S ALREADY DETAILS OF 731 00:30:37,400 --> 00:30:38,680 RESPONSIVE AND NON 732 00:30:38,680 --> 00:30:40,080 RESPONSIVENESS PAY ATTENTION TO 733 00:30:40,080 --> 00:30:43,880 ALL STATEMENTS LIKE MUST, MEET 734 00:30:43,880 --> 00:30:51,800 AND REQUIRED IN THE NOFO. 735 00:30:51,800 --> 00:30:54,960 FOR THE APPLICATION TO BE 736 00:30:54,960 --> 00:31:00,800 COMPLIANT THE MAXIMUM BUDGET IS 737 00:31:00,800 --> 00:31:03,800 $500,000 IN GRAD COSTS AND FOR 738 00:31:03,800 --> 00:31:09,120 THE R33 IS $700,000 A YEAR 739 00:31:09,120 --> 00:31:10,840 DEPENDING ON THE PHASE. 740 00:31:10,840 --> 00:31:15,720 THE MAXIMUM IS A COMBINED IS 741 00:31:15,720 --> 00:31:20,680 FIVE YEARS UP TO THREE YEARS FOR 742 00:31:20,680 --> 00:31:23,040 THE R61 PHASE AND COMPONENTS 743 00:31:23,040 --> 00:31:25,480 LIKE FOREIGN COLLABORATORS ARE 744 00:31:25,480 --> 00:31:26,440 ALLOWED BUT FOREIGN INSTITUTIONS 745 00:31:26,440 --> 00:31:31,600 ARE NOT ELIGIBLE TO APPLY. 746 00:31:31,600 --> 00:31:34,880 FOR THE SPECIFIC AIMS CANNOT 747 00:31:34,880 --> 00:31:35,280 EXCEED ONE PAGE. 748 00:31:35,280 --> 00:31:37,160 THE RESEARCH STRATEGY CANNOT 749 00:31:37,160 --> 00:31:38,560 HAVE MORE THAN 12 PAGES. 750 00:31:38,560 --> 00:31:44,640 THE PAGE LIMITS ARE FOR BOTH 751 00:31:44,640 --> 00:31:51,000 PHASES COMBINED. 752 00:31:51,000 --> 00:31:55,360 APPENDIX, HAVE YOUR INSTRUCTIONS 753 00:31:55,360 --> 00:31:58,760 TO THE SF424 AND IF YOU INCLUDE 754 00:31:58,760 --> 00:31:59,640 THE APPENDIX AND IT'S NOT 755 00:31:59,640 --> 00:32:02,480 ALLOWED ACCORDING TO THE POLICY 756 00:32:02,480 --> 00:32:07,400 OR SPECIFICALLY LISTED BY THE 757 00:32:07,400 --> 00:32:09,120 NOFO YOU RISK THE SUBMISSION TO 758 00:32:09,120 --> 00:32:13,240 BE DROPPED. 759 00:32:13,240 --> 00:32:18,320 THE NOFO ALLOWS POST-SUBMISSION 760 00:32:18,320 --> 00:32:23,680 MATERIALS SUCH AS PAPER ACCEPTED 761 00:32:23,680 --> 00:32:25,120 FOR PUBLICATION AND THEY'RE 762 00:32:25,120 --> 00:32:26,320 LISTED HERE. 763 00:32:26,320 --> 00:32:27,560 REMEMBER THAT. 764 00:32:27,560 --> 00:32:28,640 THE SUBMISSION MATERIALS SHOULD 765 00:32:28,640 --> 00:32:31,680 BE SUBMITTED AT LEAST 30 DAYS 766 00:32:31,680 --> 00:32:32,960 PRIOR TO THE PEER REVIEW 767 00:32:32,960 --> 00:32:33,200 MEETING. 768 00:32:33,200 --> 00:32:40,400 AT THE END OF THE PUBLIC HEALTH 769 00:32:40,400 --> 00:32:41,800 INFORMATION OF COVID-19 THE 770 00:32:41,800 --> 00:32:48,720 FLEXIBILITY NO LONGER APPLY. 771 00:32:48,720 --> 00:32:53,880 PRELIMINARY DATA ARE NOT 772 00:32:53,880 --> 00:32:57,120 ALLOWED. 773 00:32:57,120 --> 00:33:01,360 THE GOVERNMENT HAS TO HAVE THIS 774 00:33:01,360 --> 00:33:04,760 ATTACHED AND THE TRANSITION 775 00:33:04,760 --> 00:33:07,640 CRITERIA REQUIRED TO BE 776 00:33:07,640 --> 00:33:09,800 SUBMITTED AND DATA MANAGEMENT 777 00:33:09,800 --> 00:33:10,560 AND SHARING PLAN. 778 00:33:10,560 --> 00:33:16,360 SO THE DATA MANAGEMENT AND 779 00:33:16,360 --> 00:33:22,640 SHARING PLANS AND THE IDEA IS 780 00:33:22,640 --> 00:33:24,560 THEY'RE ONLY ASSESSED WITH COSTS 781 00:33:24,560 --> 00:33:30,960 ASSOCIATED WITH IMPLEMENTING AS 782 00:33:30,960 --> 00:33:38,080 A PLAN AND THE REQUIREMENT FOR 783 00:33:38,080 --> 00:33:42,840 SUBMISSIONS YOU NEED IN THE 784 00:33:42,840 --> 00:33:44,680 INTRODUCTION TO SUMMARIZE 785 00:33:44,680 --> 00:33:46,560 SPECIAL CHANGES AND ADDITIONS 786 00:33:46,560 --> 00:33:47,800 AND DIMENSIONS TO THE 787 00:33:47,800 --> 00:33:49,200 APPLICATION AND RESPONDING TO 788 00:33:49,200 --> 00:33:55,680 THE PRIOR REVIEW. 789 00:33:55,680 --> 00:34:01,120 HERE IS AN OVERVIEW OF THE 790 00:34:01,120 --> 00:34:04,480 REVIEW CRITERIA. 791 00:34:04,480 --> 00:34:07,920 THERE'S AN APPROACH AS WELL AS 792 00:34:07,920 --> 00:34:12,200 ADDITIONAL CRITERIA FOR THE OVER 793 00:34:12,200 --> 00:34:13,440 ALL IMPACT SCORE. 794 00:34:13,440 --> 00:34:14,320 AND ADDITIONAL REVIEW CRITERIA 795 00:34:14,320 --> 00:34:19,200 SPECIFIC FOR THIS NOFO. 796 00:34:19,200 --> 00:34:21,200 PLEASE MAKE SURE YOU HAVE THIS 797 00:34:21,200 --> 00:34:22,720 IN YOUR APPLICATION. 798 00:34:22,720 --> 00:34:25,240 THERE WOULD BE TWO PHASES. 799 00:34:25,240 --> 00:34:31,520 ONE AND TWO AND THREE AND 800 00:34:31,520 --> 00:34:32,720 REVIEWERS PROVIDE ONLY PROPOSED 801 00:34:32,720 --> 00:34:37,920 PHASES. 802 00:34:37,920 --> 00:34:40,000 ADDITIONAL LANGUAGE HAS BEEN 803 00:34:40,000 --> 00:34:43,120 ADDED TO THE STANDARD CRITERIA 804 00:34:43,120 --> 00:34:44,760 AND REVIEWERS WILL BE ASKED TO 805 00:34:44,760 --> 00:34:46,320 ADDRESS THE STANDARD AND NOFO 806 00:34:46,320 --> 00:34:48,400 SPECIFIC LANGUAGE. 807 00:34:48,400 --> 00:34:52,320 FOR EXAMPLE, FOR SIGNIFICANCE 808 00:34:52,320 --> 00:34:56,080 YOU CAN SEE THE NOVO SPECIFIC 809 00:34:56,080 --> 00:35:01,000 CRITERIA ON THIS SLIDE. 810 00:35:01,000 --> 00:35:04,600 SO PLEASE MAKE SURE YOU TAKE 811 00:35:04,600 --> 00:35:05,880 INTO CONSIDERATION OF THE REVIEW 812 00:35:05,880 --> 00:35:06,440 CRITERIA IN PREPARING YOUR 813 00:35:06,440 --> 00:35:11,480 APPLICATION. 814 00:35:11,480 --> 00:35:16,520 IN ADDITION, REVIEWERS WILL BE 815 00:35:16,520 --> 00:35:17,920 ASKED TO ADDRESS AND MATCH WHAT 816 00:35:17,920 --> 00:35:19,840 APPLICANTS NEED TO ADDRESS IN 817 00:35:19,840 --> 00:35:21,360 THE APPLICATION. 818 00:35:21,360 --> 00:35:25,040 HERE IS AN EXAMPLE. 819 00:35:25,040 --> 00:35:26,680 THERE'S A RESEARCH STRATEGY OF 820 00:35:26,680 --> 00:35:26,960 THE NOFO. 821 00:35:26,960 --> 00:35:30,400 APPLICANTS ARE ASKED TO IMPLY 822 00:35:30,400 --> 00:35:35,640 ONE OR MORE OF TECHNOLOGIES TO 823 00:35:35,640 --> 00:35:38,000 DIFFERENTIATE HEALTHY FROM 824 00:35:38,000 --> 00:35:41,120 DISEASED MYOFASCIAL UNITS IN THE 825 00:35:41,120 --> 00:35:46,960 CLINICAL PAIN CONDITION AND 826 00:35:46,960 --> 00:35:50,720 THEY'LL APPROACH A QUANTITATIVE 827 00:35:50,720 --> 00:35:53,160 TECHNOLOGY JUSTIFIED FOR THE 828 00:35:53,160 --> 00:35:56,160 QUANTITATIVE MEASURES TO 829 00:35:56,160 --> 00:35:57,400 DIFFERENTIATE THE DISEASED OR 830 00:35:57,400 --> 00:36:03,600 HEALTHY STATE OF THE MYOFASCIAL 831 00:36:03,600 --> 00:36:05,120 UNITS. 832 00:36:05,120 --> 00:36:07,440 AND MILESTONES ARE ONE 833 00:36:07,440 --> 00:36:09,600 ADDITIONAL CRITERIA. 834 00:36:09,600 --> 00:36:11,320 THIS REVIEW CRITERIA IN THE 835 00:36:11,320 --> 00:36:11,640 APPLICATION. 836 00:36:11,640 --> 00:36:17,120 PLEASE MAKE SURE YOUR 837 00:36:17,120 --> 00:36:21,560 APPLICATION HAS THESE PARTS. 838 00:36:21,560 --> 00:36:26,760 AN APPLICATIONS WILL BE REVIEWED 839 00:36:26,760 --> 00:36:28,560 BY THE SPECIAL EMPHASIS PANEL 840 00:36:28,560 --> 00:36:31,160 AND SELECTED IN THE EXPERTISE IN 841 00:36:31,160 --> 00:36:35,800 THE NOFO AND ASSIGNED IN 842 00:36:35,800 --> 00:36:36,680 PROPOSED APPLICATIONS. 843 00:36:36,680 --> 00:36:39,200 REVIEWERS WILL BE ORIENTED TO 844 00:36:39,200 --> 00:36:44,440 USE ADDITIONAL CRITERIA SUCH 845 00:36:44,440 --> 00:36:46,560 ADDS MILESTONES AND PLEASE KEEP 846 00:36:46,560 --> 00:36:48,640 IN MIND TO ADDRESS HOW YOUR 847 00:36:48,640 --> 00:36:51,280 APPLICATION WOULD BE IMPACTFUL 848 00:36:51,280 --> 00:36:53,120 CONSIDERING THE GOALS OF THE 849 00:36:53,120 --> 00:36:56,280 NOFO. 850 00:36:56,280 --> 00:36:59,760 HERE ARE KEY DATES. 851 00:36:59,760 --> 00:37:02,560 THE DUE DATE FOR THE END IS 852 00:37:02,560 --> 00:37:04,960 SEPTEMBER 1. 853 00:37:04,960 --> 00:37:09,000 LETTER OF INTENT IS DESIRED BUT 854 00:37:09,000 --> 00:37:10,200 NOT REQUIRED. 855 00:37:10,200 --> 00:37:11,880 WE ENCOURAGE YOU TO SUBMIT A 856 00:37:11,880 --> 00:37:13,440 LETTER OF INTENT TO PREPARE FOR 857 00:37:13,440 --> 00:37:16,040 THE REVIEW OF THE APPLICATIONS. 858 00:37:16,040 --> 00:37:20,760 PLEASE SEND YOUR LETTER OF 859 00:37:20,760 --> 00:37:26,680 INTENT TO DR. JESSICA McKLVEEN 860 00:37:26,680 --> 00:37:28,800 AND USE THIS FOR THE SUBMISSION 861 00:37:28,800 --> 00:37:34,680 AND RESUBMISSION UP TO OCTOBER 862 00:37:34,680 --> 00:37:34,840 18. 863 00:37:34,840 --> 00:37:35,880 PLEASE MAKE SURE YOU SUBMIT YOUR 864 00:37:35,880 --> 00:37:40,880 APPLICATION BEFORE THE DUE DATE. 865 00:37:40,880 --> 00:37:42,800 REVIEW MEETING AROUND JANUARY 866 00:37:42,800 --> 00:37:43,640 2024. 867 00:37:43,640 --> 00:37:45,120 IN SUMMARY, PLEASE MAKE SURE 868 00:37:45,120 --> 00:37:46,840 YOUR APPLICATION IS RESPONSIVE 869 00:37:46,840 --> 00:37:51,800 TO THE NOFO, HAS ALL COMPONENTS 870 00:37:51,800 --> 00:37:56,800 REQUIRED AND DOES NOT HAVE 871 00:37:56,800 --> 00:37:59,360 DOCUMENTS NOT ALLOWED AND 872 00:37:59,360 --> 00:38:00,520 FINALLY PLEASE SUBMIT YOUR 873 00:38:00,520 --> 00:38:01,600 APPLICATION BEFORE THE DEADLINE. 874 00:38:01,600 --> 00:38:02,480 THANK YOU AND LET US KNOW IF YOU 875 00:38:02,480 --> 00:38:09,120 HAVE ANY QUESTIONS. 876 00:38:09,120 --> 00:38:10,120 >>AWESOME. 877 00:38:10,120 --> 00:38:11,400 THANK YOU TO MY PRESENTERS AND 878 00:38:11,400 --> 00:38:17,680 NOW THE LONG AWAITED Q&A TIME. 879 00:38:17,680 --> 00:38:19,360 I SEE WE HAVE A FEW QUESTIONS 880 00:38:19,360 --> 00:38:19,600 ALREADY. 881 00:38:19,600 --> 00:38:21,040 I DO WANT TO CLARIFY SOMETHING 882 00:38:21,040 --> 00:38:23,440 FOR THE PEOPLE THAT HAVE ENTERED 883 00:38:23,440 --> 00:38:27,760 THIS VIDEO CAST THROUGH ZOOM, 884 00:38:27,760 --> 00:38:29,680 YOUR SCREEN HAS A Q&A FEATURE AT 885 00:38:29,680 --> 00:38:35,440 THE BOTTOM OF THE SCREEN SO YOU 886 00:38:35,440 --> 00:38:39,360 CAN SUBMIT YOUR QUESTIONS 887 00:38:39,360 --> 00:38:41,280 THROUGH THAT Q&A FEATURE AND IF 888 00:38:41,280 --> 00:38:46,160 YOU ENTERED THROUGH YOUR 889 00:38:46,160 --> 00:38:47,920 VIDEOCAST WE HAVE A FEEDBACK 890 00:38:47,920 --> 00:38:48,800 FORUM SO YOU CAN SUBMIT THEM 891 00:38:48,800 --> 00:38:50,800 THAT WAY THROUGH THE VIDEOCAST. 892 00:38:50,800 --> 00:38:51,800 WE'RE READY TO ANSWER YOUR 893 00:38:51,800 --> 00:38:53,160 QUESTIONS. 894 00:38:53,160 --> 00:38:55,880 LET'S GET STARTED. 895 00:38:55,880 --> 00:38:59,320 FIRST QUESTION, IS THERE A 896 00:38:59,320 --> 00:39:00,680 SPECIFIC PROCESS FOR 897 00:39:00,680 --> 00:39:02,480 RESUBMITTING A PROPOSAL TO THE 898 00:39:02,480 --> 00:39:06,200 HEAL SOLICITATION FROM LAST 899 00:39:06,200 --> 00:39:07,440 YEAR, FOR EXAMPLE, SHOULD ONE 900 00:39:07,440 --> 00:39:09,760 USE AN ADDITIONAL PAGE TO 901 00:39:09,760 --> 00:39:10,840 RESPOND TO THE RELEVANT -- 902 00:39:10,840 --> 00:39:13,840 EXCUSE ME TO THE REVIEWERS 903 00:39:13,840 --> 00:39:15,960 COMMENTS FROM THE PREVIOUS 904 00:39:15,960 --> 00:39:19,280 SUBMISSION SO THAT WAS LAST 905 00:39:19,280 --> 00:39:19,480 YEAR. 906 00:39:19,480 --> 00:39:19,680 ALEX? 907 00:39:19,680 --> 00:39:20,880 >>DR. HUANG ADDRESSED THIS 908 00:39:20,880 --> 00:39:21,920 DURING HIS SLIDE SO WOULD YOU 909 00:39:21,920 --> 00:39:26,800 LIKE TO ANSWER THIS QUESTION? 910 00:39:26,800 --> 00:39:30,000 >>YEAH, SO YOU SUBMIT YOUR 911 00:39:30,000 --> 00:39:31,840 APPLICATION AS A RESUBMISSION 912 00:39:31,840 --> 00:39:35,440 YOU NEED TO CHECK THE TYPE OF 913 00:39:35,440 --> 00:39:36,920 APPLICATION AS RESUBMISSION AND 914 00:39:36,920 --> 00:39:40,240 ALSO THE INTRODUCTION THAT 915 00:39:40,240 --> 00:39:41,120 SUMMARIZES THE ADDITION OR 916 00:39:41,120 --> 00:39:44,920 CHANGE OF YOUR APPLICATION OR 917 00:39:44,920 --> 00:39:47,440 RESPONSE TO THE PRIOR YEAR. 918 00:39:47,440 --> 00:39:48,760 >>THANK YOU. 919 00:39:48,760 --> 00:39:51,480 THE NEXT QUESTION IS MY FIRST 920 00:39:51,480 --> 00:39:54,800 SUBMISSION, WHICH WAS LAST YEAR, 921 00:39:54,800 --> 00:40:00,760 FOCUSSED ON LOW BACK. 922 00:40:00,760 --> 00:40:02,760 CAN I STILL FOCUS ON LOW BACK IN 923 00:40:02,760 --> 00:40:03,320 THE RESUBMISSION? 924 00:40:03,320 --> 00:40:07,320 >>YES, THANK YOU. 925 00:40:07,320 --> 00:40:11,400 AS WE NOTED, THE PAIN 926 00:40:11,400 --> 00:40:12,720 POPULATIONS RESPONSIVE WERE 927 00:40:12,720 --> 00:40:13,920 DESCRIBED IN THE FIRST. 928 00:40:13,920 --> 00:40:16,640 I THINK WE JUST PRIORITIZED 929 00:40:16,640 --> 00:40:17,880 SPECIFIC POPULATIONS WE'RE 930 00:40:17,880 --> 00:40:20,960 HOPING CAN EXPAND THE OVER ALL 931 00:40:20,960 --> 00:40:26,560 PAIN PLAN BUT BOTH THE OMT AS A 932 00:40:26,560 --> 00:40:28,760 THERAPY STILL RESPONSIVE TO THE 933 00:40:28,760 --> 00:40:31,880 R33 PHASE AS A MANIPULATION. 934 00:40:31,880 --> 00:40:35,240 SO WE DON'T SEE ANY PROBLEM WITH 935 00:40:35,240 --> 00:40:38,280 OMT BEING RESPONSIVE TO THE R33. 936 00:40:38,280 --> 00:40:41,440 >>THANK YOU, DR. TUTTLE. 937 00:40:41,440 --> 00:40:47,160 THE NEXT QUESTION IS OSTEOPATHIC 938 00:40:47,160 --> 00:40:49,080 MANIPULATIVE TREATMENT PRACTICED 939 00:40:49,080 --> 00:40:51,320 FROM D.O. PHYSICIANS CONSIDERED 940 00:40:51,320 --> 00:40:53,920 IN THE MANIPULATIVE THERAPY 941 00:40:53,920 --> 00:40:54,160 PROCEDURE. 942 00:40:54,160 --> 00:40:55,160 >>I COMBINED THESE TWO 943 00:40:55,160 --> 00:40:56,720 QUESTIONS TOGETHER WHEN I WAS 944 00:40:56,720 --> 00:40:57,760 READING THEM. 945 00:40:57,760 --> 00:40:59,840 IT'S MY FAULT. 946 00:40:59,840 --> 00:41:02,640 LOW BACK PAIN IS STILLIVE AS A 947 00:41:02,640 --> 00:41:05,440 PAIN TYPE AND O.M.T. IS STILL 948 00:41:05,440 --> 00:41:09,240 RESPONSIVE AS A POTENTIAL 949 00:41:09,240 --> 00:41:10,680 THERAPY. 950 00:41:10,680 --> 00:41:13,160 IT BLED INTO THE O.M.T. BUT 951 00:41:13,160 --> 00:41:17,400 SHOULD BE THE CASE. 952 00:41:17,400 --> 00:41:19,040 >>THE NEXT QUESTION IS IS THE 953 00:41:19,040 --> 00:41:21,760 NUMBER OF PATIENTS IN THE 954 00:41:21,760 --> 00:41:22,360 PROPOSAL IMPORTANT? 955 00:41:22,360 --> 00:41:25,120 FOR EXAMPLE, 25 PATIENTS WOULD 956 00:41:25,120 --> 00:41:29,160 THAT SUFFICE IN A GOOD SIGN -- 957 00:41:29,160 --> 00:41:32,600 WELL DESIGNED PROPOSAL? 958 00:41:32,600 --> 00:41:35,600 >>SO YOUR APPLICATION DOES NOT 959 00:41:35,600 --> 00:41:37,800 NEED TO BE POWERED TO DETERMINE 960 00:41:37,800 --> 00:41:38,480 EFFICACY. 961 00:41:38,480 --> 00:41:39,800 THAT'S NOT THE PRIMARY PURPOSE 962 00:41:39,800 --> 00:41:42,640 OF THE R33 OR NOFO IN GENERAL, 963 00:41:42,640 --> 00:41:44,600 HOWEVER, WE DO WANT YOU TO 964 00:41:44,600 --> 00:41:46,800 DESCRIBE IN YOUR SPECIFIC 965 00:41:46,800 --> 00:41:48,960 MILESTONES A QUANTITATIVE 966 00:41:48,960 --> 00:41:50,960 THRESHOLD OR A SIGNIFICANT 967 00:41:50,960 --> 00:41:53,000 DIFFERENCE BETWEEN HEALTHY AND 968 00:41:53,000 --> 00:41:53,640 DISEASED TISSUE STATES. 969 00:41:53,640 --> 00:41:56,280 YOU'LL NEED TO COME UP WITH 970 00:41:56,280 --> 00:41:57,160 EXPERIMENTS AND POWER 971 00:41:57,160 --> 00:41:59,120 CALCULATIONS SUFFICIENT TO 972 00:41:59,120 --> 00:42:01,680 DEMONSTRATE A MODERATE AFFECT 973 00:42:01,680 --> 00:42:03,000 SIZE, FOR EXAMPLE, AS LISTED IN 974 00:42:03,000 --> 00:42:04,920 THE NOFO. 975 00:42:04,920 --> 00:42:08,640 I CAN'T SAY SPECIFICALLY WHAT 976 00:42:08,640 --> 00:42:09,240 YOU'RE CLINICAL POPULATION 977 00:42:09,240 --> 00:42:10,720 SHOULD BE HOWEVER, YOU NEED TO 978 00:42:10,720 --> 00:42:12,040 KEEP IN MIND YOU'LL BE ASSESSED 979 00:42:12,040 --> 00:42:14,320 BY REVIEW ON THE MILESTONES YOU 980 00:42:14,320 --> 00:42:14,560 INCLUDE. 981 00:42:14,560 --> 00:42:16,680 YOU NEED TO KEEP THE POWER 982 00:42:16,680 --> 00:42:18,400 CALCULATIONS IN MIND. 983 00:42:18,400 --> 00:42:20,960 >>NEXT QUESTION, BESIDES 984 00:42:20,960 --> 00:42:24,320 IMAGING TECHNOLOGIES MENTIONED 985 00:42:24,320 --> 00:42:25,120 IN THE WEBINAR, CAN NOVEL 986 00:42:25,120 --> 00:42:28,320 MEASURES ALSO BE USED BY 987 00:42:28,320 --> 00:42:31,600 INVASIVE MEASURES SUCH AS BLOOD 988 00:42:31,600 --> 00:42:32,760 SAMPLING AND TISSUE CODES. 989 00:42:32,760 --> 00:42:34,040 ARE THOSE ALLOWABLE? 990 00:42:34,040 --> 00:42:39,920 >>SO WE ARE NOT ALLOWING HIGHLY 991 00:42:39,920 --> 00:42:41,520 INVASIVE THRESHOLDS OR 992 00:42:41,520 --> 00:42:42,040 QUANTITATIVE MEASURES OR 993 00:42:42,040 --> 00:42:44,960 ASSESSMENTS. 994 00:42:44,960 --> 00:42:46,560 BASED ON WHAT THIS QUESTION IS 995 00:42:46,560 --> 00:42:48,000 ALLUDING TO, I DON'T BELIEVE 996 00:42:48,000 --> 00:42:48,560 THAT WOULD BE DEEMED TO BE 997 00:42:48,560 --> 00:42:50,760 RESPONSIVE. 998 00:42:50,760 --> 00:42:53,080 WE'RE INSTEAD LOOKING FOR 999 00:42:53,080 --> 00:42:59,000 MINIMALLY INVASIVE OR 1000 00:42:59,000 --> 00:43:00,280 NON-INVASIVE ASSESSMENTS TO 1001 00:43:00,280 --> 00:43:05,120 MEASURE QUANTITATIVE THRESHOLDS. 1002 00:43:05,120 --> 00:43:07,760 >>NEXT QUESTION, CAN BLOOD WORK 1003 00:43:07,760 --> 00:43:10,160 AND ENERGY HEALING APPLY TO THIS 1004 00:43:10,160 --> 00:43:15,200 NOFO? 1005 00:43:15,200 --> 00:43:17,560 >>SO, I'M ASSUMING THIS PERSON 1006 00:43:17,560 --> 00:43:20,280 IS TALKING SPECIFICALLY ABOUT 1007 00:43:20,280 --> 00:43:23,840 THE INTERVENTION THAT THEY WOULD 1008 00:43:23,840 --> 00:43:27,320 EMPLOY DURING THE R33 PHASE. 1009 00:43:27,320 --> 00:43:30,080 WE ARE ALLOWING ADDITIONAL 1010 00:43:30,080 --> 00:43:30,680 THERAPEUTIC TYPES TO BE 1011 00:43:30,680 --> 00:43:31,120 PROPOSED. 1012 00:43:31,120 --> 00:43:34,920 HOWEVER, YOU NEED TO HAVE A 1013 00:43:34,920 --> 00:43:36,480 STRONGLY -- A STRONG REASONING 1014 00:43:36,480 --> 00:43:39,120 AND RATIONALE FOR HOW YOU 1015 00:43:39,120 --> 00:43:41,680 BELIEVE YOUR CHOSEN INTERVENTION 1016 00:43:41,680 --> 00:43:45,440 WOULD LEAD TO A DEMONSTRABLE OR 1017 00:43:45,440 --> 00:43:46,080 MEASURABLE DIFFERENCE BETWEEN 1018 00:43:46,080 --> 00:43:47,760 TISSUE AT BASELINE AND AFTER THE 1019 00:43:47,760 --> 00:43:48,080 INTERVENTION. 1020 00:43:48,080 --> 00:43:50,800 THE IDEA IS THAT THE 1021 00:43:50,800 --> 00:43:52,480 INTERVENTION IS TO PERTURB THE 1022 00:43:52,480 --> 00:43:55,000 MYOFASCIAL UNIT, LOOK AT CHANGES 1023 00:43:55,000 --> 00:43:56,040 IN THE MYOFASCIAL UNIT BEFORE 1024 00:43:56,040 --> 00:43:57,760 AND AFTER THE INTERVENTION BASED 1025 00:43:57,760 --> 00:43:59,840 ON THE THRESHOLD YOU'VE 1026 00:43:59,840 --> 00:44:04,080 DEVELOPED IN YOUR R61 PHASE. 1027 00:44:04,080 --> 00:44:06,480 UNLIKE THE FIRST ISSUE WHERE WE 1028 00:44:06,480 --> 00:44:09,960 WERE RELEGATED TO CERTAIN TYPES 1029 00:44:09,960 --> 00:44:12,200 HOWEVER, REVIEW WILL BE 1030 00:44:12,200 --> 00:44:14,960 EVALUATING WHETHER THERE IS A 1031 00:44:14,960 --> 00:44:18,960 STRONG RATIONALE FOR THE 1032 00:44:18,960 --> 00:44:20,160 INTERVENTION TO SEE A DIFFERENCE 1033 00:44:20,160 --> 00:44:21,360 IN THE MYOFASCIAL UNIT. 1034 00:44:21,360 --> 00:44:21,840 YOU HAVE TO BRING THE 1035 00:44:21,840 --> 00:44:22,320 JUSTIFICATION TO THE 1036 00:44:22,320 --> 00:44:26,120 APPLICATION. 1037 00:44:26,120 --> 00:44:27,120 >>THE NEXT QUESTION -- AND 1038 00:44:27,120 --> 00:44:28,720 THANK YOU FOR THE GREAT 1039 00:44:28,720 --> 00:44:31,040 QUESTIONS, KEEP THEM COMING. 1040 00:44:31,040 --> 00:44:38,280 ARE DATA-DRIVEN A.I./M.L. MODELS 1041 00:44:38,280 --> 00:44:40,400 ACCEPTABLE FOR DISCOVERY OF S OR 1042 00:44:40,400 --> 00:44:44,000 IS THE EMPHASIS ON 1043 00:44:44,000 --> 00:44:44,560 HYPOTHESIS-DRIVEN APPROACH 1044 00:44:44,560 --> 00:44:50,960 GENERALLY THE CASE AT NIH? 1045 00:44:50,960 --> 00:44:52,760 >>WELL, I DON'T NECESSARILY 1046 00:44:52,760 --> 00:44:57,560 WANT TO SPEAK TO OTHER FUNDING 1047 00:44:57,560 --> 00:44:59,200 OPPORTUNITIES AVAILABLE FOR A.I. 1048 00:44:59,200 --> 00:45:02,160 OR MACHINE LEARNING RESEARCH AND 1049 00:45:02,160 --> 00:45:06,680 WHETHER THE OTHER RFAs ARE 1050 00:45:06,680 --> 00:45:07,200 HYPOTHESIS DRIVEN OR NOT. 1051 00:45:07,200 --> 00:45:11,960 IN THE CASE OF THIS NOFO WE DO 1052 00:45:11,960 --> 00:45:13,160 SUPPORT A.I. OR MACHINE LEARNING 1053 00:45:13,160 --> 00:45:14,960 COMPOSITE MEASURES BEING USED TO 1054 00:45:14,960 --> 00:45:19,600 LOOK AT COMPOSITES OR MULTIPLE 1055 00:45:19,600 --> 00:45:21,440 PERI METRIC OR MULTI-MODAL 1056 00:45:21,440 --> 00:45:24,440 IMAGING OR MINIMALLY INVASIVE 1057 00:45:24,440 --> 00:45:24,960 TECHNIQUES. 1058 00:45:24,960 --> 00:45:27,040 AGAIN, THERE WAS THE BIOMARKER 1059 00:45:27,040 --> 00:45:29,160 IN THE ONE SLIDE HOWEVER, WE ARE 1060 00:45:29,160 --> 00:45:32,960 NOT REQUIRING YOU DEVELOP A 1061 00:45:32,960 --> 00:45:37,840 BIOMARKER AT THIS STAGE FOR THIS 1062 00:45:37,840 --> 00:45:39,360 NOVO IT'S TO DEVELOP 1063 00:45:39,360 --> 00:45:40,480 QUANTITATIVE MEASURES OR 1064 00:45:40,480 --> 00:45:41,840 THRESHOLDS THAT COULD BECOME A 1065 00:45:41,840 --> 00:45:42,880 BIOMARKER THROUGH MORE RESEARCH 1066 00:45:42,880 --> 00:45:44,960 BUT THIS IS MORE UPSTREAM OF 1067 00:45:44,960 --> 00:45:46,920 THAT. 1068 00:45:46,920 --> 00:45:56,960 IF YOU ARE GOING TO PROPOSE A 1069 00:45:56,960 --> 00:46:00,000 A.I./M.L. IT SHOULD BE WHAT WAS 1070 00:46:00,000 --> 00:46:02,560 MENTIONED IN THE REVIEW OR 1071 00:46:02,560 --> 00:46:02,840 APPLICATION. 1072 00:46:02,840 --> 00:46:09,160 >>AND TO DRAW ATTENTION TO 1073 00:46:09,160 --> 00:46:12,120 FREQUE 1074 00:46:12,120 --> 00:46:13,160 FREQUENTLY ASKED QUESTIONS ON 1075 00:46:13,160 --> 00:46:14,960 THE NCCIH WEBSITE. 1076 00:46:14,960 --> 00:46:17,160 SOME QUESTIONS YOU'RE ANSWERING 1077 00:46:17,160 --> 00:46:18,760 ARE SIMILAR TO THE FREQUENTLY 1078 00:46:18,760 --> 00:46:20,320 ASKED QUESTIONS RECEIVED PRIOR 1079 00:46:20,320 --> 00:46:20,960 TO THE WEBINAR. 1080 00:46:20,960 --> 00:46:22,320 I THINK YOU'LL FIND THOSE 1081 00:46:22,320 --> 00:46:22,520 HELPFUL. 1082 00:46:22,520 --> 00:46:25,120 I'LL ASK A REVIEW QUESTION. 1083 00:46:25,120 --> 00:46:28,760 SO SHIYONG, WITH TWO PHASES, THE 1084 00:46:28,760 --> 00:46:30,400 R61 AND R33, HOW WILL MY 1085 00:46:30,400 --> 00:46:38,600 APPLICATION BE SCORED? 1086 00:46:38,600 --> 00:46:38,960 AUTO 1087 00:46:38,960 --> 00:46:44,200 >>THANK YOU FOR THIS QUESTION. 1088 00:46:44,200 --> 00:46:49,720 WE'LL PROVIDE ONE SO THE R61 AND 1089 00:46:49,720 --> 00:46:50,360 R33 PHASE. 1090 00:46:50,360 --> 00:46:50,880 THEY'RE COMBINED FOR BOTH 1091 00:46:50,880 --> 00:46:56,360 PHASES. 1092 00:46:56,360 --> 00:46:58,640 >>GREAT, LET ME FOLLOW-UP WITH 1093 00:46:58,640 --> 00:47:01,160 THIS QUESTION, WILL MILESTONES 1094 00:47:01,160 --> 00:47:01,960 INFLUENCE THE SCORE? 1095 00:47:01,960 --> 00:47:08,960 >>YES, SO MILESTONES IS AN 1096 00:47:08,960 --> 00:47:13,960 ADDITIONAL CRITERION AND IN 1097 00:47:13,960 --> 00:47:18,960 ALLOWING THE CRITERIA TO PRODUCE 1098 00:47:18,960 --> 00:47:20,960 AN IMPACT SCORE AND HOW IT'S 1099 00:47:20,960 --> 00:47:22,680 BALANCED DEPENDS ON THE 1100 00:47:22,680 --> 00:47:25,160 REVIEWER'S JUDGMENT. 1101 00:47:25,160 --> 00:47:25,680 >>ALL RIGHT. 1102 00:47:25,680 --> 00:47:27,200 THE NEXT QUESTION, IS THERE A 1103 00:47:27,200 --> 00:47:29,280 LETTER OF INTENT THAT CAN BE 1104 00:47:29,280 --> 00:47:32,160 USED AS A GUIDE FOR FIRST-TIME 1105 00:47:32,160 --> 00:47:33,440 APPLICANTS TO VIEW TO KNOW IF 1106 00:47:33,440 --> 00:47:36,960 THEY ARE PROVIDING YOU THE 1107 00:47:36,960 --> 00:47:38,880 CORRECT INFORMATION AND FORMAT 1108 00:47:38,880 --> 00:47:43,600 FOR THE FIRST SUBMISSION? 1109 00:47:43,600 --> 00:47:49,040 >>YEAH, SO, I CAN ANSWER THE 1110 00:47:49,040 --> 00:47:49,320 QUESTION. 1111 00:47:49,320 --> 00:47:56,960 A LETTER OF INTENT IS NOT 1112 00:47:56,960 --> 00:48:01,160 REQUIRED OR BINDING AND IT 1113 00:48:01,160 --> 00:48:11,680 ALLOWS US, STAFF, TO PLAN THE 1114 00:48:13,200 --> 00:48:13,600 REVIEW. 1115 00:48:13,600 --> 00:48:15,000 BASICALLY WE WANT TO KNOW IF 1116 00:48:15,000 --> 00:48:18,000 YOU'RE GOING SUBMIT THE 1117 00:48:18,000 --> 00:48:20,960 APPLICATION AND WHAT KIND OF 1118 00:48:20,960 --> 00:48:22,600 PERSONNEL WILL BE THERE AND WHAT 1119 00:48:22,600 --> 00:48:26,600 RESEARCH WE ARE GOING TO HAVE 1120 00:48:26,600 --> 00:48:26,880 PROPOSED. 1121 00:48:26,880 --> 00:48:29,360 THAT'S THE BASIC INFORMATION WE 1122 00:48:29,360 --> 00:48:30,280 WANT TO KNOW. 1123 00:48:30,280 --> 00:48:36,280 AND YOU CAN SUBMIT YOUR FORM 1124 00:48:36,280 --> 00:48:38,320 APPLICATION AND CAN BE CHANGED 1125 00:48:38,320 --> 00:48:39,680 BECAUSE THE LETTER OF INTENT IS 1126 00:48:39,680 --> 00:48:41,000 NOT PART OF THE APPLICATION. 1127 00:48:41,000 --> 00:48:43,000 >>ALEX, IS THERE ANYTHING YOU 1128 00:48:43,000 --> 00:48:43,640 WANT TO SAY? 1129 00:48:43,640 --> 00:48:44,960 I SAW YOU TYPING. 1130 00:48:44,960 --> 00:48:47,920 >>SORRY, I'M NOT MUTED SO YOU 1131 00:48:47,920 --> 00:48:49,160 PROBABLY HEARD THE TYPING. 1132 00:48:49,160 --> 00:48:52,720 I RESPONDED WITH A LINK TO THE 1133 00:48:52,720 --> 00:48:54,760 NIAID FOR WHAT THE BEST 1134 00:48:54,760 --> 00:48:57,040 PRACTICES ARE FOR LETTER OF 1135 00:48:57,040 --> 00:48:59,840 INTENT, ETCETERA. 1136 00:48:59,840 --> 00:49:01,680 THIS MAY HELP THE POTENTIAL 1137 00:49:01,680 --> 00:49:03,800 APPLICANT WRITE A LETTER OF 1138 00:49:03,800 --> 00:49:04,200 INTENT. 1139 00:49:04,200 --> 00:49:05,880 JUST SOME BEST PRACTICES THERE. 1140 00:49:05,880 --> 00:49:07,880 >>THAT'S GOOD INFORMATION. 1141 00:49:07,880 --> 00:49:08,280 OKAY. 1142 00:49:08,280 --> 00:49:13,760 NEXT QUESTION, ARE FASCIA 1143 00:49:13,760 --> 00:49:17,160 TISSUES INCLUDING METAGENES 1144 00:49:17,160 --> 00:49:18,520 BEING CONSIDERED IN THE RFA? 1145 00:49:18,520 --> 00:49:21,880 >>AS WE MENTIONED, COMPONENTS 1146 00:49:21,880 --> 00:49:23,360 OF THE MYOFASCIAL UNIT ARE 1147 00:49:23,360 --> 00:49:29,320 WITHIN THE SCOPE OF THIS RFA. 1148 00:49:29,320 --> 00:49:33,960 A RATIONALE JUSTIFICATION FOR 1149 00:49:33,960 --> 00:49:37,600 MYOFASCIAL TISSUE AND TO ASSESS 1150 00:49:37,600 --> 00:49:39,400 IN THE PHASE WILL BE REQUIRED 1151 00:49:39,400 --> 00:49:47,360 AND IT'S UP TO THE APPLICANT TO 1152 00:49:47,360 --> 00:49:48,760 SUBMIT AND THEY CAN FOLLOW UP IF 1153 00:49:48,760 --> 00:49:50,800 THEY HAVE ADDITIONAL QUESTIONS. 1154 00:49:50,800 --> 00:49:53,000 >>WHAT IS THE BEST PERSON OR 1155 00:49:53,000 --> 00:49:54,600 E-MAIL TO ASK ANY ADDITIONAL 1156 00:49:54,600 --> 00:49:55,200 QUESTIONS INCLUDING PROPOSED 1157 00:49:55,200 --> 00:49:57,480 THERAPIES? 1158 00:49:57,480 --> 00:50:01,160 I CAN FOLLOW UP WITH YOU ON THAT 1159 00:50:01,160 --> 00:50:02,800 AT THE END OF THE WEBINAR, I'LL 1160 00:50:02,800 --> 00:50:03,920 LIST THAT INFORMATION AND POINT 1161 00:50:03,920 --> 00:50:05,160 OF CONTACT AN REVIEW AND 1162 00:50:05,160 --> 00:50:11,200 PROGRAM. 1163 00:50:11,200 --> 00:50:13,160 >>AS I MENTIONED WE HAVE 1164 00:50:13,160 --> 00:50:16,240 PROGRAM CONTACTS SO IF THERE'S 1165 00:50:16,240 --> 00:50:19,360 SOMEBODY YOU PREFER TO REACH OUT 1166 00:50:19,360 --> 00:50:22,000 YOU CAN LOOK AT THE LIST OF 1167 00:50:22,000 --> 00:50:25,600 NAMES OR ME AND I BELIEVE WE 1168 00:50:25,600 --> 00:50:27,480 HAVE A HEAL SHARED INBOX. 1169 00:50:27,480 --> 00:50:31,480 YOU CAN'T GO WRONG WRITING TO 1170 00:50:31,480 --> 00:50:32,840 THAT IN BOX BECAUSE WE'RE ALL ON 1171 00:50:32,840 --> 00:50:33,160 IT. 1172 00:50:33,160 --> 00:50:36,200 >>PROBABLY YOU ALL WERE INVITED 1173 00:50:36,200 --> 00:50:38,560 TO THIS WEBINAR FROM AN 1174 00:50:38,560 --> 00:50:40,080 INVITATION FROM US COMING FROM 1175 00:50:40,080 --> 00:50:41,120 THAT MAILBOX SO PLEASE USE THAT 1176 00:50:41,120 --> 00:50:46,520 TO RESPOND. 1177 00:50:46,520 --> 00:50:46,720 OKAY. 1178 00:50:46,720 --> 00:50:48,520 WHAT IS THE DURATION AND BUDGET 1179 00:50:48,520 --> 00:50:53,360 FOR THE R61 AND R33 PHASES. 1180 00:50:53,360 --> 00:50:56,960 ALEX, WOULD YOU LIKE TO ANSWER 1181 00:50:56,960 --> 00:50:58,040 THAT. 1182 00:50:58,040 --> 00:51:00,120 I THINK SHIYONG IS AVAILABLE. 1183 00:51:00,120 --> 00:51:04,360 >>WE EXPECT TO MAKE UP TO FIVE 1184 00:51:04,360 --> 00:51:06,600 AWARDS THIS TIME AND FOR THE 1185 00:51:06,600 --> 00:51:08,800 SPECIFIC PHASES I THINK 1186 00:51:08,800 --> 00:51:10,920 DR. HUANG GO OVER THIS BUT DO 1187 00:51:10,920 --> 00:51:14,080 YOU WANT TO REITERATE, SHIYONG? 1188 00:51:14,080 --> 00:51:24,600 >>YEAH, SO FOR THE BUDGET LI 1189 00:51:25,200 --> 00:51:27,840 LIMIT -- I'M TRYING TO FIND THE 1190 00:51:27,840 --> 00:51:32,600 INFORMATION FOR THE R61 IS 1191 00:51:32,600 --> 00:51:40,000 $500,000 IN DIRECT COSTS PER 1192 00:51:40,000 --> 00:51:43,520 YEAR AND R33 IS $700,000 1193 00:51:43,520 --> 00:51:44,960 DEPENDING ON THE PHASE. 1194 00:51:44,960 --> 00:51:48,760 >>WE STRONGLY DISCOURAGE 1195 00:51:48,760 --> 00:51:50,760 APPLICATIONS FOR A ONE YEAR 1196 00:51:50,760 --> 00:51:51,480 DEVELOPMENT BECAUSE WE'RE 1197 00:51:51,480 --> 00:51:52,960 EXPECTING YOU TO COME UP WITH 1198 00:51:52,960 --> 00:51:57,000 NOVEL QUANTITATIVE MEASURES OR 1199 00:51:57,000 --> 00:51:59,000 THRESHOLDS LEVERAGING NEW OR 1200 00:51:59,000 --> 00:52:00,480 EXISTING TECHNOLOGIES THAT CAN 1201 00:52:00,480 --> 00:52:06,560 BE LEVERAGED IN THIS NEW AREA. 1202 00:52:06,560 --> 00:52:08,560 WE EXPECT THE TECHNOLOGY PORTION 1203 00:52:08,560 --> 00:52:13,360 SO WE STRESS A TWO-YEAR PHASE OF 1204 00:52:13,360 --> 00:52:15,480 $500,000 PER YEAR AND THE DIRECT 1205 00:52:15,480 --> 00:52:20,080 COSTS DEPENDS ON A TWO-YEAR OR 1206 00:52:20,080 --> 00:52:22,200 THREE-YEAR R61 PHASE SO COLLECT 1207 00:52:22,200 --> 00:52:24,200 THE NUMBERS FOR THE SPECIFIC 1208 00:52:24,200 --> 00:52:24,800 NOFO AGAIN. 1209 00:52:24,800 --> 00:52:27,000 >>ARE BOTH QUANTITATIVE AND 1210 00:52:27,000 --> 00:52:30,440 QUALITATIVE MEASURES ACCEPTABLE? 1211 00:52:30,440 --> 00:52:32,960 IF YES OR NO, A SIGNIFICANT 1212 00:52:32,960 --> 00:52:36,120 MEASURE? 1213 00:52:36,120 --> 00:52:39,760 >>SO WE EXPECT THIS TO BE 1214 00:52:39,760 --> 00:52:41,160 QUANTITATIVE MEASURES. 1215 00:52:41,160 --> 00:52:43,720 A QUALITATIVE MEASURE I DON'T 1216 00:52:43,720 --> 00:52:45,400 THINK WOULD BE RESPONSIVE TO 1217 00:52:45,400 --> 00:52:46,200 THIS NOFO. 1218 00:52:46,200 --> 00:52:49,360 HOWEVER, I WILL SAY THAT IF YOU 1219 00:52:49,360 --> 00:52:50,720 HAVE ANY QUESTIONS IT'S BETTER 1220 00:52:50,720 --> 00:52:52,360 TO REACH OUT TO YOUR PROGRAM 1221 00:52:52,360 --> 00:52:54,280 OFFICERS EARLIER RATHER THAN 1222 00:52:54,280 --> 00:52:58,120 SUBMITTING YOUR 12-PAGE PLUS ALL 1223 00:52:58,120 --> 00:53:01,120 YOUR 398 AND ALL THE OTHER 1224 00:53:01,120 --> 00:53:03,000 PAPERWORK IF YOU'RE NOT SURE 1225 00:53:03,000 --> 00:53:03,480 WHAT'S RESPONSIVE. 1226 00:53:03,480 --> 00:53:06,960 IT'S BETTER TO CONTACT US EARLY 1227 00:53:06,960 --> 00:53:09,000 SO PLEASE CONTACT US IF YOU HAVE 1228 00:53:09,000 --> 00:53:09,560 QUESTIONS. 1229 00:53:09,560 --> 00:53:12,720 >>CAN I SUBMIT MY APPLICATION 1230 00:53:12,720 --> 00:53:12,920 LATE? 1231 00:53:12,920 --> 00:53:17,160 >>I CAN FIELD THIS QUESTION. 1232 00:53:17,160 --> 00:53:19,600 NO, YOU CANNOT SUBMIT YOUR 1233 00:53:19,600 --> 00:53:24,440 APPLICATION LATE. 1234 00:53:24,440 --> 00:53:26,960 THE NOFO HAS LATE SUBMISSION IS 1235 00:53:26,960 --> 00:53:32,480 NOT ALLOWED. 1236 00:53:32,480 --> 00:53:35,360 PLEASE SUBMIT AS EARLY AS AS 1237 00:53:35,360 --> 00:53:35,800 POSSIBLE. 1238 00:53:35,800 --> 00:53:38,120 >>YOU HEARD IT HERE, BE LATE, 1239 00:53:38,120 --> 00:53:38,880 BE LEFT OUT. 1240 00:53:38,880 --> 00:53:41,760 CAN YOU CLARIFY THE DIFFERENCE 1241 00:53:41,760 --> 00:53:44,560 IN ELIGIBILITY BETWEEN FOREIGN 1242 00:53:44,560 --> 00:53:45,000 COMPONENTS AND 1243 00:53:45,000 --> 00:53:51,320 NON-U.S. INSTITUTIONS? 1244 00:53:51,320 --> 00:53:55,240 >>YES. 1245 00:53:55,240 --> 00:54:00,320 COMPONENTS ALLOW AS PART OF THE 1246 00:54:00,320 --> 00:54:02,920 SUBMISSION. 1247 00:54:02,920 --> 00:54:05,120 AND THE FOREIGN INSTITUTION OR 1248 00:54:05,120 --> 00:54:06,720 FOREIGN COMPONENT OF THE 1249 00:54:06,720 --> 00:54:13,120 INSTITUTIONS IS NOT ELIGIBLE TO 1250 00:54:13,120 --> 00:54:15,000 BE SUBMITTED. 1251 00:54:15,000 --> 00:54:17,680 >>GRET. 1252 00:54:17,680 --> 00:54:17,960 -- GREAT. 1253 00:54:17,960 --> 00:54:19,840 LET ME JUST CHECK HERE. 1254 00:54:19,840 --> 00:54:25,520 I HAVE ONE LAST QUESTION. 1255 00:54:25,520 --> 00:54:29,720 IS THE MYOFASCIAL UNIT AND UPPER 1256 00:54:29,720 --> 00:54:31,080 EXTREMITY PAIN IN STRESS 1257 00:54:31,080 --> 00:54:37,160 DISORDER RELEVANT TO THIS NOFO? 1258 00:54:37,160 --> 00:54:41,000 >>WE HAVE A QUESTION FROM THE 1259 00:54:41,000 --> 00:54:41,160 FAQ. 1260 00:54:41,160 --> 00:54:43,160 LET ME GO BACK TO WHAT WE WROTE. 1261 00:54:43,160 --> 00:54:46,600 SO THIS WAS AN EXAMPLE THAT WE 1262 00:54:46,600 --> 00:54:48,520 GAVE IN THE FAQ SAYING THAT IF 1263 00:54:48,520 --> 00:54:51,000 AN APPLICANT WOULD LIKE TO MAKE 1264 00:54:51,000 --> 00:54:52,360 A CASE THAT WE'RE GOING TO 1265 00:54:52,360 --> 00:54:53,560 STRESS DISORDER IS RELEVANT TO 1266 00:54:53,560 --> 00:54:54,360 THE NOFO. 1267 00:54:54,360 --> 00:54:57,400 YOU NEED TO EXPLAIN THE 1268 00:54:57,400 --> 00:55:00,000 RELEVANCE OF THE MYOFASCIAL UNIT 1269 00:55:00,000 --> 00:55:01,160 AND CHANGES TO THE MYOFASCIAL 1270 00:55:01,160 --> 00:55:03,000 UNIT WILL BE STUDYING IN ANY 1271 00:55:03,000 --> 00:55:05,040 PROPOSED PAIN CONDITION IN THE 1272 00:55:05,040 --> 00:55:05,320 APPLICATION. 1273 00:55:05,320 --> 00:55:07,600 IT DOESN'T HAVE TO BE THE 1274 00:55:07,600 --> 00:55:10,520 PRESCRIBED TYPE OF PAIN THAT WE 1275 00:55:10,520 --> 00:55:14,920 ARE CALLING FOR IN THIS RFA. 1276 00:55:14,920 --> 00:55:18,680 HOWEVER, YOU NEED TO PROVIDE 1277 00:55:18,680 --> 00:55:19,800 STRONG RATIONALE FOR WHY 1278 00:55:19,800 --> 00:55:22,240 MYOFASCIAL UNIT IS IMPLICATED IN 1279 00:55:22,240 --> 00:55:23,120 THE KIND OF PAIN YOUR PROPOSED 1280 00:55:23,120 --> 00:55:27,000 TO STUDY. 1281 00:55:27,000 --> 00:55:30,920 >>OKAY. 1282 00:55:30,920 --> 00:55:36,120 I'M JUST CHECKING MY QUESTION 1283 00:55:36,120 --> 00:55:36,440 BOX. 1284 00:55:36,440 --> 00:55:37,840 THERE'S QUESTIONS PENDING AND 1285 00:55:37,840 --> 00:55:41,000 I'D LIKE TO INVITE DR. LANGEVIN 1286 00:55:41,000 --> 00:55:43,680 OR ANY OF MY OTHER TWO SPEAKERS 1287 00:55:43,680 --> 00:55:46,120 TO GIVE ANY OTHER PARTING 1288 00:55:46,120 --> 00:55:49,120 REMARKS BEFORE I CLOSE DOWN THE 1289 00:55:49,120 --> 00:55:54,320 WEBINAR. 1290 00:55:54,320 --> 00:55:56,960 >>I CAN SAY A FEW WORDS. 1291 00:55:56,960 --> 00:56:02,760 SO AS DR. TUTTLE EXPLAINED VERY 1292 00:56:02,760 --> 00:56:06,800 NICELY, OUR FOCUS IN THE REISSUE 1293 00:56:06,800 --> 00:56:09,720 IS TO ALLOW, FIRST OF ALL PEOPLE 1294 00:56:09,720 --> 00:56:12,120 WHO HAD ALREADY SUBMITTED 1295 00:56:12,120 --> 00:56:14,240 APPLICATIONS THAT DID NOT GET 1296 00:56:14,240 --> 00:56:16,480 FUNDED BUT THAT RECEIVED 1297 00:56:16,480 --> 00:56:20,320 FEEDBACK FROM THE REVIEW AND AN 1298 00:56:20,320 --> 00:56:24,160 OPPORTUNITY TO RESUBMIT. 1299 00:56:24,160 --> 00:56:25,760 THE AREAS OF PREVIOUS AREAS OF 1300 00:56:25,760 --> 00:56:27,760 FOCUS ARE STILL VALID. 1301 00:56:27,760 --> 00:56:31,040 HOWEVER, WHAT WE NOTICED IN THE 1302 00:56:31,040 --> 00:56:34,000 APPLICATION S THAT WE FUNDED 1303 00:56:34,000 --> 00:56:39,000 BEFORE IS THERE WERE AREAS WHERE 1304 00:56:39,000 --> 00:56:41,840 WE DID NOT HAVE ACTUALLY DID NOT 1305 00:56:41,840 --> 00:56:44,440 RECEIVE APPLICATIONS THAT WERE 1306 00:56:44,440 --> 00:56:45,520 FUNDABLE OR RECEIVE APPLICATIONS 1307 00:56:45,520 --> 00:56:46,440 AT ALL IN THE AREAS. 1308 00:56:46,440 --> 00:56:48,560 THOSE ARE THE SPECIFIC AREAS 1309 00:56:48,560 --> 00:56:52,800 THAT DR. TUTTLE HIGHLIGHTED IN 1310 00:56:52,800 --> 00:56:55,280 HIS AREAS OF SPECIAL INTEREST IN 1311 00:56:55,280 --> 00:56:57,040 THIS REISSUE BUT THEY'RE NOT 1312 00:56:57,040 --> 00:56:57,520 MEANT TO BE EXCLUSIVE. 1313 00:56:57,520 --> 00:57:01,160 THAT'S IMPORTANT. 1314 00:57:01,160 --> 00:57:03,920 AND SAME THING WITH THE KINDS OF 1315 00:57:03,920 --> 00:57:06,160 THERAPIES THAT ARE CONSIDERED 1316 00:57:06,160 --> 00:57:07,880 RESPONSIVE VERSUS NON-RESPONSIVE 1317 00:57:07,880 --> 00:57:09,800 AND A LOT OF THOSE QUESTIONS 1318 00:57:09,800 --> 00:57:11,600 WERE ANSWERED VERY NICELY BUT IF 1319 00:57:11,600 --> 00:57:14,280 YOU HAVE ANY FURTHER QUESTIONS, 1320 00:57:14,280 --> 00:57:18,280 CONTACT THE PROGRAM STAFF AND 1321 00:57:18,280 --> 00:57:19,920 HOPEFULLY THERE ARE LOTS OF YOU 1322 00:57:19,920 --> 00:57:21,080 OUT THERE THAT WILL BE INSPIRED 1323 00:57:21,080 --> 00:57:23,760 TO SEND US APPLICATIONS AND WE 1324 00:57:23,760 --> 00:57:28,920 LOOK FORWARD TO RECEIVING THEM. 1325 00:57:28,920 --> 00:57:35,240 >>ALEX OR SHIYONG? 1326 00:57:35,240 --> 00:57:36,960 ARE YOU GOOD? 1327 00:57:36,960 --> 00:57:37,680 >>ANY CLOSING COMMENTS? 1328 00:57:37,680 --> 00:57:40,160 >>YOU CAN IF YOU WANT TO. 1329 00:57:40,160 --> 00:57:42,160 I'M JUST INVITING YOU IF YOU 1330 00:57:42,160 --> 00:57:43,120 WANT TO. 1331 00:57:43,120 --> 00:57:44,800 >>I WANT TO SAY MAKE SURE YOU 1332 00:57:44,800 --> 00:57:48,040 ARE HAVE ALL THE COMPONENTS IN 1333 00:57:48,040 --> 00:57:50,560 THE APPLICATION AND MAKE SURE 1334 00:57:50,560 --> 00:57:51,880 IT'S RESPONSIVE AND COMPLETE AND 1335 00:57:51,880 --> 00:57:56,440 SUBMITTED. 1336 00:57:56,440 --> 00:57:58,520 >>I WOULD SAY PROBABLY THE MOST 1337 00:57:58,520 --> 00:57:59,840 IMPORTANT THING IS BECAUSE YOU 1338 00:57:59,840 --> 00:58:02,800 STILL HAVE TIME AS YOU WRITE THE 1339 00:58:02,800 --> 00:58:04,400 APPLICATION REACH OUT TO PROGRAM 1340 00:58:04,400 --> 00:58:07,560 STAFF IF YOU HAVE QUESTIONS. 1341 00:58:07,560 --> 00:58:09,200 IT'S BETTER TO GET FEEDBACK 1342 00:58:09,200 --> 00:58:11,120 RATHER THAN WAITING UNTIL AFTER 1343 00:58:11,120 --> 00:58:13,080 SUBMISSION AND FINDING OUT YOU 1344 00:58:13,080 --> 00:58:14,840 DID NOT WRITE A RESPONSIVE 1345 00:58:14,840 --> 00:58:15,160 APPLICATION. 1346 00:58:15,160 --> 00:58:19,440 I WANT TO REITERATE AGAIN THIS 1347 00:58:19,440 --> 00:58:24,240 IS A MASSIVE EFFORT SO I HAVE 1348 00:58:24,240 --> 00:58:27,040 MANY TO THANK FOR CO-LEADING THE 1349 00:58:27,040 --> 00:58:31,160 INITIATIVE AND REISSUE AND THE 1350 00:58:31,160 --> 00:58:35,320 SEVEN OTHER I.C.s WHO HELPED 1351 00:58:35,320 --> 00:58:37,960 REISSUE THE RFA AND HELP AS THE 1352 00:58:37,960 --> 00:58:39,720 SUBMISSIONS COME IN. 1353 00:58:39,720 --> 00:58:42,600 THANK YOU FOR THE TEAM AND FOR 1354 00:58:42,600 --> 00:58:45,040 DR. LANGEVIN FOR GIVING THE 1355 00:58:45,040 --> 00:58:47,200 SCOPE AND HISTORY OF THE FIRST 1356 00:58:47,200 --> 00:58:51,440 ISSUE AND THANK YOU, ANITA, FOR 1357 00:58:51,440 --> 00:58:52,440 ORGANIZING THE TECHNICAL 1358 00:58:52,440 --> 00:58:53,160 ASSISTANCE WEBINAR AND 1359 00:58:53,160 --> 00:58:54,200 MODERATING TODAY. 1360 00:58:54,200 --> 00:58:55,360 >>IT'S MY PLEASURE. 1361 00:58:55,360 --> 00:58:57,560 I WANT TO THANK ONE MORE TIME 1362 00:58:57,560 --> 00:59:00,480 OUR PRESENTERS, DR. LANGEVIN AND 1363 00:59:00,480 --> 00:59:03,000 DR. TUTTLE AND DR. HUANG. 1364 00:59:03,000 --> 00:59:04,040 THANK YOU SO MUCH FOR YOUR WELL 1365 00:59:04,040 --> 00:59:04,920 PREPARED PRESENTATIONS. 1366 00:59:04,920 --> 00:59:06,320 I THINK THEY'LL HAVE A BIG 1367 00:59:06,320 --> 00:59:07,840 IMPACT AND AGAIN THANK YOU TO 1368 00:59:07,840 --> 00:59:08,680 OUR VIEWING AUDIENCE. 1369 00:59:08,680 --> 00:59:12,120 YOU'RE VERY IMPORTANT TO US AND 1370 00:59:12,120 --> 00:59:14,400 YOUR QUESTIONS WERE RIGHT ON PAR 1371 00:59:14,400 --> 00:59:16,240 WE THANK YOU FOR JOINING THE 1372 00:59:16,240 --> 00:59:18,040 WEBINAR AND THE EVENT IS BEING 1373 00:59:18,040 --> 00:59:19,200 VIDEOCAST AND WILL BE ARCHIVED 1374 00:59:19,200 --> 00:59:21,880 FOR LATER VIEWING SO TOMORROW 1375 00:59:21,880 --> 00:59:25,000 AROUND THIS TIME YOU SHOULD BE 1376 00:59:25,000 --> 00:59:28,040 ABLE TO RETRIEVE IT FROM THE NIH 1377 00:59:28,040 --> 00:59:30,640 EVENTS SITE UNDER PREVIOUS 1378 00:59:30,640 --> 00:59:30,880 WEBINARS. 1379 00:59:30,880 --> 00:59:33,040 ALSO, YOU WILL RECEIVE AN E-MAIL 1380 00:59:33,040 --> 00:59:34,360 FROM ME LATER TODAY WITH A 1381 00:59:34,360 --> 00:59:36,600 SURVEY REQUESTING YOUR FEEDBACK. 1382 00:59:36,600 --> 00:59:38,440 IT TAKES ABOUT TWO MINUTES TO 1383 00:59:38,440 --> 00:59:40,960 COMPLETE AND YOUR FEEDBACK IS 1384 00:59:40,960 --> 00:59:43,040 VERY IMPORTANT TO US AS WE 1385 00:59:43,040 --> 00:59:45,120 CONTINUE TO SHAPE FUTURE 1386 00:59:45,120 --> 00:59:46,800 WEBINARS MUCH INTEREST TO YOU. 1387 00:59:46,800 --> 00:59:54,720 LET ME GO TO THE NEXT SLIDE. 1388 00:59:54,720 --> 00:59:59,600 >>LET ME BRING IT UP. 1389 00:59:59,600 --> 01:00:01,360 >>I SAW ALL THE HAND GESTURES. 1390 01:00:01,360 --> 01:00:03,080 >>I WASN'T SURE WHETHER I WAS 1391 01:00:03,080 --> 01:00:04,360 DRIVING THIS OR NOT. 1392 01:00:04,360 --> 01:00:05,920 >>WHILE WE'RE WAITING, WHAT I'M 1393 01:00:05,920 --> 01:00:10,080 DOING IS PROMOTING THE SECOND 1394 01:00:10,080 --> 01:00:13,120 PART OF THIS WEBINAR SERIES 1395 01:00:13,120 --> 01:00:18,120 WHICH WILL BE ON AUGUST 16 FROM 1396 01:00:18,120 --> 01:00:20,840 11:00 TO 12:15, A DIFFERENT 1397 01:00:20,840 --> 01:00:25,160 TIME, SAME DAY BUT WE HOPE 1398 01:00:25,160 --> 01:00:27,120 YOU'LL TAKE PART IN THIS 1399 01:00:27,120 --> 01:00:30,560 NETWORKING WEBINAR DESIGN TO 1400 01:00:30,560 --> 01:00:31,520 FACILITATE CONVERSATIONS WITH 1401 01:00:31,520 --> 01:00:33,160 PROGRAM OFFICIALS AND TOPIC 1402 01:00:33,160 --> 01:00:35,560 EXPERTS RELATED TO THE TECHNICAL 1403 01:00:35,560 --> 01:00:37,160 REQUIREMENTS OF THE R33 PHASE OF 1404 01:00:37,160 --> 01:00:38,720 THE FUNDING OPPORTUNITY. 1405 01:00:38,720 --> 01:00:40,880 SO WE HOPE YOU CAN JOIN US NEXT 1406 01:00:40,880 --> 01:00:41,080 WEEK. 1407 01:00:41,080 --> 01:00:41,880 I THINK IT WOULD BE BENEFICIAL 1408 01:00:41,880 --> 01:00:45,680 TO YOU. 1409 01:00:45,680 --> 01:00:51,400 PLEASE FOLLOW-UP WITH DR. ALEX 1410 01:00:51,400 --> 01:00:52,720 TUTTLE, THE NCCIH DIRECTOR IF 1411 01:00:52,720 --> 01:00:55,640 YOU HAVE QUESTIONS RELATED TO 1412 01:00:55,640 --> 01:00:58,120 NCCIH OR WANT TO DISCUSS YOUR 1413 01:00:58,120 --> 01:01:00,240 PROJECT AIMS IN MORE DETAIL. 1414 01:01:00,240 --> 01:01:04,200 FOR REVIEW QUESTIONS FOLLOW-UP 1415 01:01:04,200 --> 01:01:07,280 WITH THE DIRECTOR OF THE NCCIH 1416 01:01:07,280 --> 01:01:08,400 OFFICE OF SCIENTIFIC REVIEW AND 1417 01:01:08,400 --> 01:01:12,440 WHO IS A REVIEW CONTACT ON THE 1418 01:01:12,440 --> 01:01:12,640 NOFO. 1419 01:01:12,640 --> 01:01:15,160 AGAIN, THANK YOU FOR YOUR 1420 01:01:15,160 --> 01:01:17,080 PARTICIPATION IN THIS WEBINAR 1421 01:01:17,080 --> 01:01:17,280 TODAY. 1422 01:01:17,280 --> 01:01:20,520 WE HOPE IT WAS CONSISTENT AND 1423 01:01:20,520 --> 01:01:22,320 CLARIFIED YOUR KEY 1424 01:01:22,320 --> 01:01:23,040 CONSIDERATIONS AND QUESTIONS 1425 01:01:23,040 --> 01:01:24,080 DURING THE APPLICATION AND 1426 01:01:24,080 --> 01:01:27,160 REVIEW PROCESS. 1427 01:01:27,160 --> 01:01:29,680 SEE YOU NEXT WEEK FOR PART TWO. 1428 01:01:29,680 --> 01:01:40,200 ENJOY THE REMAINDER OF YOUR DAY.